Open Nav

Filtered by:

Clear All
Wednesday, October 17
8:30am Navigating Checkpoint Inhibitors’ Clinical Results: Lessons for CEOs and Investors Kenneth LaMontagne, The Leukemia & Lymphoma Society; Karin Jooss, Gritstone Oncology; Eugene P. Kennedy, NewLink Genetics; Angèle Maki, Merck & Co; Thomas W. Dubensky Jr., Tempest Therapeutics show more Time Wednesday, Oct 17 8:30AM - 9:40AM Questions

Submit panelist questions here.

Speakers Kenneth LaMontagne The Leukemia & Lymphoma Society Karin Jooss Gritstone Oncology Eugene P. Kennedy NewLink Genetics Angèle Maki Merck & Co Thomas W. Dubensky Jr. Tempest Therapeutics
9:00am Aegle Therapeutics Corp. Shelley Hartman, Aegle Therapeutics Corporation show more Company Description/Mission Statement Aegle Therapeutics Corp. is a first in class, Phase I/IIa-ready, biotechnology company isolating extracellular vesicles (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells (“BM-MSCs”) to treat severe dermatological conditions. Aegle’s platform technology is initially being developed to treat epidermolysis bullosa (“EB”), a rare pediatric skin blistering disorder, and burns (including scarring prevention). Aegle has been cleared by the FDA to enter the clinic to treat burn patients with its EV therapy. Aegle will be filing an additional IND for the treatment of dystrophic EB with its EV therapy in the fourth quarter of 2018. Aegle was founded to harness the regenerative healing power of mesenchymal stem cells without using the cells as therapy. While EVs are the paracrine wound healing mediators of cells, they are not living, and therefore may provide a safe, lower cost alternative to using cells as therapy. Time Wednesday, Oct 17 9:00AM - 9:15AM Location Elizabethan D Speakers Shelley Hartman Aegle Therapeutics Corporation Handa Pharmaceuticals, Inc. Stephen Cary, Handa Pharmaceuticals, Inc. show more Company Description/Mission Statement Working with medical experts, Handa identifies unmet medical needs that can be addressed by improving marketed medicines using innovative drug delivery technologies. Handa will create significant value by developing, owning and monetizing innovative intellectual property, and commercializing its products globally. Time Wednesday, Oct 17 9:00AM - 9:15AM Location Elizabethan A Speakers Stephen Cary Handa Pharmaceuticals, Inc. MaxCyte, Inc. Douglas Doerfler, MaxCyte, Inc. show more Company Description/Mission Statement MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA™ is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with 9 of the top 10 global biopharma companies, and has 55+ partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. Time Wednesday, Oct 17 9:00AM - 9:15AM Location Elizabethan C Speakers Douglas Doerfler MaxCyte, Inc. Poxel SA Noah Beerman, Poxel SA show more Company Description/Mission Statement Poxel uses its development expertise in metabolism to advance drug candidates focused on the treatment of metabolic disorders, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Imeglimin Phase 3 program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC), is in Phase 1 and being developed for NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. Time Wednesday, Oct 17 9:00AM - 9:15AM Location Olympic Speakers Noah Beerman Poxel SA Sartar Therapeutics Harri Sihto, Sartar Therapeutics show more Company Description/Mission Statement Sartar Therapeutics develops a new targeted therapy for orphan cancer, gastrointestinal stromal tumor (GIST) based on discovery of novel oncogenes, phosphodiesterase 3 enzymes and repositioning and reformulation of an off-patent drug, anagrelide. The majority of GISTs become resistant for currently approved therapies. Anagrelide shows efficacy in those tumors and complements efficacy of Gleevec (Novartis) the current first-line therapy option for the patients. Sartar Develops a controlled-release anagrelide that will be administered once a week subcutaneously for the GIST patients. The candidate product will be developed up to phase I/II clinical trials and then out-licensed or sold to industry partners. Development will take up to 5 years and cost $5M. Sartar seeks seed/series A funding to take the candidate product up to clinical study phase. Time Wednesday, Oct 17 9:00AM - 9:15AM Location Elizabethan B Speakers Harri Sihto Sartar Therapeutics
9:15am AmideBio LLC Pawel Fludzinski, AmideBio show more Company Description/Mission Statement AmideBio is a biopharmaceutical drug discovery and development company operating in the diabetes space – a market with many options, but one still hungry for innovation. The primary area of focus is in Glucose Responsive Insulins (GRIs) – a treatment paradigm that can potentially redefine how diabetes is treated. AmideBio has a novel approach to GRIs, with an ability to intelligently design insulin analogs using computational techniques, coupled with a proprietary manufacturing technology (BioPure™ Platform) which allows for the low cost, high-efficiency manufacture of insulin analogs. In a second research program, the BioPure™ platform has been used to create a series of thermally stable, soluble glucagon analogs in pursuit of an orphan drug indication for congenital hyperinsulinism. Beyond the GRI program and glucagon programs, AmideBio leverages its manufacturing technology to generate revenue through the supply of ultrapure peptides to a variety of customers. Time Wednesday, Oct 17 9:15AM - 9:30AM Location Olympic Speakers Pawel Fludzinski AmideBio Landos Biopharma Josep Bassaganya-Riera, Landos Biopharma show more Company Description/Mission Statement Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and is in Phase 1 clinical testing for Crohn’s disease and ulcerative colitis. Landos also has a robust pipeline of compounds for other autoimmune diseases. Time Wednesday, Oct 17 9:15AM - 9:30AM Location Elizabethan D Speakers Josep Bassaganya-Riera Landos Biopharma NeuExcell Therapeutics Zhenhua Wu, NeuExcell Therapeutics show more Company Description/Mission Statement NeuExcell's mission is to cure neurodegenerative diseases through our world-leading astrocyte-to-neuron conversion platforms. NeuExcell’s proprietary and patented in vivo cell conversion technology regenerates neurons from glial cells in diseased brain/spinal cord. NeuExcell is developing a gene therapy platform to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Huntington’s disease and Parkinson’s disease. Using AAV-based gene therapy, reactive glial cells inside the injured brains can be efficiently converted into functional neurons and thus lead to the restoration of lost brain functions. We have obtained solid preclinical proof-of-concept validation in mouse and monkey models of ischemic stroke. A Phase I/II clinical trial to test the safety, tolerability, behavior and imaging biomarker improvement of NXL-AAV001 gene therapy is planned to take place in 12-18 months. Time Wednesday, Oct 17 9:15AM - 9:30AM Location Elizabethan C Speakers Zhenhua Wu NeuExcell Therapeutics OncoSenX, Inc Matthew Scholz, OncoSenX show more Company Description/Mission Statement OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA. Our treatment delivers a simple genetic program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease. Time Wednesday, Oct 17 9:15AM - 9:30AM Location Elizabethan A Speakers Matthew Scholz OncoSenX Sinfonia Biotherapeutics, Inc. Bob Blomquist, Sinfonia Biotherapeutics, Inc. show more Company Description/Mission Statement Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s & Parkinson’s disorders. Our approach to developing orphan drug therapies is targeting patient subtypes and disease mechanisms that are genetically defined. To deliver our first-in-class disease-modifying therapies, we are employing our proprietary, implantable bioreactor device with cells engineered to manufacture single or multiple therapeutic factors locally within the brain. We have two drug therapies presently in preclinical development, iProg and MTA. The lead indication for our most advanced developmental therapy, iProg, is treatment for GRN-related FTD through restoration of progranulin levels. By developing patient-targeted therapies that are delivered by our bioreactor technology, we will launch breakthrough treatments for well-defined dementias and beyond. Time Wednesday, Oct 17 9:15AM - 9:30AM Location Elizabethan B Speakers Bob Blomquist Sinfonia Biotherapeutics, Inc.
9:30am AbTLAS show more Company Description/Mission Statement To enhance quality of life by providing innovative therapeutic solutions to people suffering from diseases. AbTLAS is developing innovative therapeutic antibodies for complex targets including GPCRs and ion channels through discovery of functional antibodies using FAST platform technology, which employs HTS of a spatially addressed Fv antibody library with cells expressing target of interest. Time Wednesday, Oct 17 9:30AM - 9:45AM Location Elizabethan D InMed Pharmaceuticals Inc. Eric Adams, InMed Pharmaceuticals Inc. show more Company Description/Mission Statement InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. Time Wednesday, Oct 17 9:30AM - 9:45AM Location Elizabethan C Speakers Eric Adams InMed Pharmaceuticals Inc. NeuroDiagnostics LLC Paul Tanico, NeuroDiagnostics (NDX) show more Company Description/Mission Statement NeuroDiagnostics (NDX) has developed a groundbreaking test for diagnosing Alzheimer's Disease (AD) – it is the only extremely accurate test to identify and differentiate it from other sources of dementia – called Discern™ o The test is non-invasive (2-3 millimeter skin punch biopsy already commonly performed by nurses everyday) and can distinguish between AD, non-AD and healthy patients o The test is the result of over 15 years of research at the Blanchette Rockefeller Neurosciences Institute (BRNI), now part of West Virginia University, and confirmed by subsequent brain autopsies conducted at Johns Hopkins University o The NDX test has a sensitivity (accuracy) of 95%+ and specificity (meaning it does not have false positives) of 95%+ • NDX achieved “Breakthrough Status” with the FDA this year o In August 2018, NDX submitted clinical developmental and validation data that supports the intended use of its 3 independent non-invasive Alzheimer’s Disease (AD) Biomarkers. Time Wednesday, Oct 17 9:30AM - 9:45AM Location Elizabethan B Speakers Paul Tanico NeuroDiagnostics (NDX) RxMP Therapeutic, Inc. Rifat Pamukcu, RxMP Therapeutics, Inc. show more Company Description/Mission Statement RxMP Therapeutics, Inc. (RxMP) is an emerging specialty therapeutics company focused on developing proprietary drugs for the management of excessive bleeding. RxMP aims to develop and commercialize RMP-HPEs, (red cell-derived microparticles produced by high-pressure extrusion), as a first-in-class hemostatic agent for the treatment or prevention of excessive bleeding. Our product’s initial target market is in those patients at risk of excessive bleeding during spinal surgery, a worldwide market opportunity of over $900M, with expansion potential of $4.6B in additional clinical indications of excessive bleeding. Our platform technology capitalizes on the finding that RMP-HPEs, when administered systemically in the setting of acute bleeding, will stop the bleeding without the risk of undesirable clotting elsewhere in the body. Time Wednesday, Oct 17 9:30AM - 9:45AM Location Olympic Speakers Rifat Pamukcu RxMP Therapeutics, Inc. Susavion Biosciences, Inc. J. Kenneth Hoober, Susavion Biosciences, Inc. show more Company Description/Mission Statement Susavion Biosciences provides the oncology community with novel tetravalent peptides that mimic sugars that activate the host immune system in a non-adjuvant, non-antigenic context. These peptides target immune cell pathways that direct tumor-specific killing either alone or as combination therapies. Primary mechanism(s) of action have been determined to modulate dendritic cells and macrophage populations. Our mission is to apply our technology platform to develop novel drugs that harness the power of the immune system to combat cancer and other major diseases. We developed a portfolio of therapeutic peptides that mature, activate and expand the immune cell repertoire and have achieved “proof of concept” in multiple preclinical oncology models demonstrating a strong immune response validating the technology platform. Current focus is on cancer of peritoneal organs, specifically ovarian cancer. Time Wednesday, Oct 17 9:30AM - 9:45AM Location Elizabethan A Speakers J. Kenneth Hoober Susavion Biosciences, Inc.
9:45am E-Scape Bio Julie Anne Smith, E-Scape Bio Inc. show more Company Description/Mission Statement E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. We are passionate about making a meaningful clinical impact for patients suffering from CNS diseases and believe in a genetically defined approach to achieving this goal. Time Wednesday, Oct 17 9:45AM - 10:00AM Location Elizabethan A Speakers Julie Anne Smith E-Scape Bio Inc. Imara Inc., Rahul Ballal, Imara show more Company Description/Mission Statement mara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Time Wednesday, Oct 17 9:45AM - 10:00AM Location Elizabethan B Speakers Rahul Ballal Imara Learning from Translational Research Successes to Attract Investment Simone Fishburn, BioCentury; Alice Chen , Accelerator Life Science Partners; Kevin Grimes, Stanford University; Paul Laikind, ViaCyte; Stephanie Marrus, University of California, San Francisco (UCSF); Shyam Patel, California Institute for Regenerative Medicine (CIRM) show more Time Wednesday, Oct 17 9:45AM - 10:40AM Questions

Submit panelist questions here.

Speakers Simone Fishburn BioCentury Alice Chen Accelerator Life Science Partners Kevin Grimes Stanford University Paul Laikind ViaCyte Stephanie Marrus University of California, San Francisco (UCSF) Shyam Patel California Institute for Regenerative Medicine (CIRM)
Nucleus Network Cameron Johnson, Nucleus Network show more Time Wednesday, Oct 17 9:45AM - 10:00AM Location Olympic Speakers Cameron Johnson Nucleus Network Orum Therapeutics Inc SJ Lee, Orum Therapeutics show more Company Description/Mission Statement Orum Therapeutics is a private biotech developing a new class of therapeutic antibodies to target previously undruggable proteins that are involved in aggressive cancers and severe genetic diseases. Orum's unique cell-penetrating antibody platform is easily adaptable to target specific cell types and inhibit different intracellular drug targets, without chemical modification. The company has a pipeline of preclinical therapeutic candidates, of which the most advanced targets oncogenic RAS. Time Wednesday, Oct 17 9:45AM - 10:00AM Location Elizabethan D Speakers SJ Lee Orum Therapeutics SignalRx Pharmaceuticals, Inc. Guillermo Morales, SignalRx Pharmaceuticals, Inc. show more Company Description/Mission Statement SignalRx Pharmaceuticals, Inc. is a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for cancer treatment. Our mission is to enable new levels of sophisticated combination treatments for cancer patients to help improve their quality and length of life. Time Wednesday, Oct 17 9:45AM - 10:00AM Location Elizabethan C Speakers Guillermo Morales SignalRx Pharmaceuticals, Inc.
10:00am AbbVie KT Moortgat, AbbVie show more Company Description/Mission Statement AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn. Time Wednesday, Oct 17 10:00AM - 10:15AM Location Elizabethan D Speakers KT Moortgat AbbVie Ativo TX (dba IL-2Rx Inc.) Sally Ann Reiss, Ativo TX, dba Il-2rx Inc show more Company Description/Mission Statement Ativo TX was founded by an experienced immunology clinician, a molecular biologist, and a chemist (as a spinout from Stanford Medical School). Ativo TX is creating new drug therapies that target a cell-mediated immune response pathway prevalent in major Autoimmune Disorders (Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Type 1 Diabetes). Ativo TX has a patent-protected, novel platform technology that utilizes existing FDA approved drugs in a protein-drug conjugate model. Ativo TX’s has established strategic partnerships to bring Ativo’s lead candidate drugs to market (SAB, Stanford & IBMP/Fiocruz) Time Wednesday, Oct 17 10:00AM - 10:15AM Location Elizabethan C Speakers Sally Ann Reiss Ativo TX, dba Il-2rx Inc Mezzion Pharma Erik Emerson, Mezzion Pharmaceuticals show more Company Description/Mission Statement We seek to discover new medicines and use our extensive trial experience to deliver hope to patients in areas where hope is needed. Time Wednesday, Oct 17 10:00AM - 10:15AM Location Elizabethan B Speakers Erik Emerson Mezzion Pharmaceuticals PanTher Therapeutics, Inc. Laura Indolfi, PanTher Therapeutis, Inc. show more Company Description/Mission Statement PanTher Therapeutics is working to revolutionize the treatment of inoperable, locally advanced solid tumors − studying the direct delivery of proven chemotherapy agents directly onto the tumor for consistent, slow release over time. The company designed its novel delivery method to potentially eliminate the toxic and debilitating side effects that chemo produces when delivered systemically through traditional IV/oral administration. Its first potential indication is pancreatic cancer, a particularly lethal disease where excruciating symptoms arise from primary mass invading nearby vital organs. By changing the route of administration to target just the tumor, PanTher is designed to increase amount of drug reaching the intended destination with the aim to enhance therapeutic efficacy. Eliminating adverse outcomes may also lower healthcare costs. PanTher is completing pre-clinical studies prior to initiate human trials and exploring opportunities for partnerships to expand its pipeline. Time Wednesday, Oct 17 10:00AM - 10:15AM Location Elizabethan A Speakers Laura Indolfi PanTher Therapeutis, Inc. Sindolor LLC Jon Newland, Sindolor LLC show more Company Description/Mission Statement Sindolor LLC has developed an opioid replacement and narcotic dependency treatment medicine, utilizing cannabis extract as one ingredient. The medicine is non-toxic, benign as far as side effects, economical to manufacture, and deliverable orally and by the other usual means of administration. Results from our initial exploratory Phase I non-FDA medical trial show outstanding promise, exceeding all expectations. It can replace opioids, even morphine, for pain management - with none of the dangers associated with opiates. Sindolor LLC has in development an additional four unique formulations addressing other therapeutic indications , several of which are ready for provisional patent filing. Time Wednesday, Oct 17 10:00AM - 10:15AM Location Olympic Speakers Jon Newland Sindolor LLC
10:15am Ab Studio Inc. Yue Liu, Ab Studio Inc. show more Company Description/Mission Statement Ab Studio Inc. is a technology platform company developing novel therapeutic antibodies with the following unique technologies: 1) "Imbalanced" bispecific antibody platform 2) "Serial" internalizing antibody platform. We deeply believe in "quality by design" rule and would like to contribute to the therapeutic antibody R&D field via CRO service, partnership and licensing out. Our lead program, a computational designed CD20/CD3 "imbalanced" bispecific antibody (bsAb) has significantly reduced CD3 binding affinity and high CD20 binding affinity. In vitro data showed that this bsAb "safely" maintains the effector function and has less potential to trigger cytokine storm while still has good efficacy, this bsAb also has good develop-ability due to computational optimization design. We look forward to partnering with Biopharmas to co-develop this leading program, other pipeline programs and/or to co-develop novel therapeutic antibodies with our proven technology platforms. Time Wednesday, Oct 17 10:15AM - 10:30AM Location Elizabethan C Speakers Yue Liu Ab Studio Inc. AcuraStem Incorporated Sam Alworth, AcuraStem Incorporated show more Company Description/Mission Statement AcuraStem utilizes advanced stem cell technology and artificial intelligence to predict drug efficacy for neurodegenerative disease using living neurons from current patients – a virtual nerve biopsy. AcuraStem has used this technology platform, iNeuroRX™, to discover and bring forward a novel and potentially curative preclinical ALS therapeutic candidate, winning over $4M in grant funding from the NIH and the Muscular Dystrophy Association for this effort; iNeuroRx™ was born out of research from the lab of AcuraStem’s President and co-founder Dr. Justin Ichida, and heralded in the February 5, 2018 issue of Nature Medicine. Time Wednesday, Oct 17 10:15AM - 10:30AM Location Elizabethan A Speakers Sam Alworth AcuraStem Incorporated ArTara Therapeutics, Inc. Jesse Shefferman, ArTara Therapeutics, Inc. show more Company Description/Mission Statement ArTara is a rare diseases company focused on developing de-risked assets that will have real-world impact on the lives of patients suffering from rare diseases. Our lead program, IV Choline Chloride, is an easy to understand replacement therapy for Intestinal Failure Associated Liver Disease, a fatal rare disease that affects the thousands of chronically ill patients who survive on intravenous nutrition. There are no approved therapies for IFALD. IV Choline has demonstrated promising results in IFALD patients in two Phase II studies and is further supported by decades of academic research. We are currently in End-of-Phase-2 dialogue with the FDA to outline and agree on the pivotal program design for IV Choline and anticipate we will reach agreement by end-2018. Beyond IV Choline we are active in bringing new rare disease programs to the ArTara portfolio and anticipate growth in our portfolio through 2018-2019. Time Wednesday, Oct 17 10:15AM - 10:30AM Location Elizabethan B Speakers Jesse Shefferman ArTara Therapeutics, Inc. Axolo Pharma Thomas Krol, Axolo Pharma show more Company Description/Mission Statement Axolo Pharma, Inc. is a joint venture between Trim-edicine, Inc. and Novadiol, Inc. Trim-edicine is a spinout of The Ohio State University. Novadiol is a biotech company with significant drug development experience. Axolo desires to help people through new science and has the worldwide rights (x-China) to the injectable use of MG53. Discovered by Dr. Jianjie Ma and colleagues, MG53 is a cellular repair protein. Originally discovered in muscle cells, it has a unique mechanism of action resulting in rapid healing of cellular injury due to trauma, toxin or immune mediated damage. MG53 has applications for diseases of the brain, heart, kidney, muscle, and lung. Initial development targets in include orphan diseases such as delayed graft function and ALS. Time Wednesday, Oct 17 10:15AM - 10:30AM Location Elizabethan D Speakers Thomas Krol Axolo Pharma Phoenix PharmaLabs, Inc. Bill Crossman, Phoenix PharmaLabs, Inc. show more Company Description/Mission Statement Phoenix PharmaLabs (PPL) is a preclinical drug discovery company focused on development of new potent, non-addictive treatments for pain and addiction therapy. PPL has developed a novel opioid molecule, PPL-103, that is a potent analgesic (10x stronger than morphine), but is non-addicting, does not produce withdrawal and does not cause death from overdose (even at 350x dose) or constipation (even at 100x dose). Unlike other opioids that aggressively stimulate the mu receptor (which produces euphoria), PPL-103 binds strongly to all three opioid receptors (mu, kappa and delta) - and just partially stimulates all of those receptors with very little stimulation of mu. PPL-103 has clearly demonstrated in various animal studies that it does not produce euphoria (or dysphoria). Research has shown that there is a very high correlation between these studies and human studies that measure the potential for abuse and addiction. Time Wednesday, Oct 17 10:15AM - 10:30AM Location Olympic Speakers Bill Crossman Phoenix PharmaLabs, Inc.
10:30am Amygdala Neurosciences, Inc. Peter Strumph, Amygdala Neurosciences, Inc. show more Company Description/Mission Statement Amygdala Neurosciences is developing ANS-6637 for the treatment of substance use disorder. NIH funded Phase-2 studies for opioid and alcohol use disorders will begin in 2019. We are also planning to start a Phase-2 study for smoking cessation and studies to support cocaine use disorder development in 2019. ANS-6637 is a novel Phase-2 ready, selective and reversible ALDH2 inhibitor, a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. Time Wednesday, Oct 17 10:30AM - 10:45AM Location Elizabethan C Speakers Peter Strumph Amygdala Neurosciences, Inc. ChemioCare Pedro Lichtinger, ChemioCare show more Company Description/Mission Statement Transforming the treatment of chemotherapy induced nausea and vomiting (CINV) through transdermal patch technology. Time Wednesday, Oct 17 10:30AM - 10:45AM Location Elizabethan A Speakers Pedro Lichtinger ChemioCare Locus Biosciences, Inc. Paul Garofolo, Locus Biosciences, Inc. show more Company Description/Mission Statement Locus is developing powerful CRISPR-engineered bacteriophage (“crPhage”) products that kill target bacteria by irreversibly destroying their DNA while leaving the many species of good bacteria in the body unharmed. Our platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacteriophage. By bringing these technologies together, Locus is creating products that kill bacterial pathogens effectively with safety profiles that far exceed those of traditional antibiotics. crPhage therapies can address any bacterial pathogen at any site of infection, including those responsible for deadly acute infections and microbiome-associated diseases. Time Wednesday, Oct 17 10:30AM - 10:45AM Location Elizabethan D Speakers Paul Garofolo Locus Biosciences, Inc. Opsidio, LLC Martin Philips, Opsidio show more Company Description/Mission Statement Opsidio is developing OpSCF, a monoclonal antibody with a novel target that effectively treats the chronic inflammation that leads to fibrosis. OpSCF is highly effective in 5 independent animal models of fibrosis and remodeling. The first clinical indication will be glomerulonephritis, a subset of CKD, for which there is no effective therapy. OpSCF also shows promise in diabetic and hypertensive kidney disease, which affect millions of patients. OpSCF improves survival in an animal model of renal fibrosis. OpSCF normalizes profibrotic cytokine levels, decreases fibrosis and returns activated myofibroblasts to a quiescent state. OpSCF is highly specific for its target as demonstrated by a high-dose, non-GLP toxicology study that showed no adverse events. OpSCF is humanized, and ready for GMP manufacturing and IND-enabling studies. We are seeking Series A funding, and are 15 months from IND. Time Wednesday, Oct 17 10:30AM - 10:45AM Location Elizabethan B Speakers Martin Philips Opsidio Theracaine, LLC Mark Schwartz, Theracaine show more Company Description/Mission Statement The company is developing non-opioid, long acting pain medicines for post surgical indications which will provide the patient with long acting relief, the surgeon with pain relief solutions tailored to each surgery and patient, payers with affordable pain management solutions and investors with a low risk path to a large market Time Wednesday, Oct 17 10:30AM - 10:45AM Location Olympic Speakers Mark Schwartz Theracaine
10:45am BioXcel Therapeutics Vimal Mehta, BioXcel Therapeutics show more Company Description/Mission Statement A Clinical Stage Biopharmaceutical Company Advancing the Next Wave of Medicines in Neuroscience & Immuno-Oncology. Time Wednesday, Oct 17 10:45AM - 11:00AM Location Elizabethan C Speakers Vimal Mehta BioXcel Therapeutics Circle Pharma, Inc. show more Company Description/Mission Statement Circle is developing intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular targets, and can be delivered by oral administration. Our macrocycle development platform is applicable across a wide range of serious diseases; we are initially focusing our internal development efforts on intracellular protein-protein interactions that are key drivers in molecularly defined cancers, including Cyclin A : cdk2, Cyclin E : cdk2, and beta-catenin. In addition, we have built a pilot physical library of cell permeable macrocycles. We are open to partnering opportunities to apply our macrocycle platform to targets that are challenging to address with conventional small molecule or biologics. We are currently raising a Series A-1 round of $10M to advance our pipeline to animal proof of concept ($5M received at the first closing) and anticipate raising a larger series B round in late 2019 to fund through to clinical data. Time Wednesday, Oct 17 10:45AM - 11:00AM Location Elizabethan A SFA Therapeutics, LLC Ira Spector, SFA Therapeutics show more Company Description/Mission Statement SFA Therapeutics, LLC is a development-stage bio-pharmaceutical company focused on a new advancement in the treatment inflammatory diseases. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's Disease, Psoriasis, Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), and even cancer. Our microbiome-derived drugs are derived from natural substances identified at Temple University, and enable a new platform for developing treatments potentially aimed at over 85 potential inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is Psoriasis and Liver Disease (Hepatitis B, NASH and HCC). Patents have been filed in both of these diseases, based on animal data in Liver Disease and on a small human case-controlled trial ex-US in Psoriasis. Additional patents are filed in Uveitis, CRS (CAR-T) and neonatal allergies. Time Wednesday, Oct 17 10:45AM - 11:00AM Location Elizabethan B Speakers Ira Spector SFA Therapeutics Using Microbiome-Based Therapies to Improve Patient Outcomes Wenyuan Shi, Forsyth Institute; David Berry , Flagship Pioneering; Karim Dabbagh, Second Genome, Inc.; Glyn Edwards, Summit Therapeutics; Paul Miller, Synlogic; Lihi Segal, DayTwo; Emma Taylor, Naked Biome show more Time Wednesday, Oct 17 10:45AM - 11:40AM Questions

Submit panelist questions here.

Speakers Wenyuan Shi Forsyth Institute David Berry Flagship Pioneering Karim Dabbagh Second Genome, Inc. Glyn Edwards Summit Therapeutics Paul Miller Synlogic Lihi Segal DayTwo Emma Taylor Naked Biome
XOMA Corporation Tom Burns, XOMA Corporation show more Company Description/Mission Statement XOMA has built a portfolio of over two dozen products that are licensed to and being developed by other biotech and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future. For more information, visit www.xoma.com. Time Wednesday, Oct 17 10:45AM - 11:00AM Location Elizabethan D Speakers Tom Burns XOMA Corporation ZeClinics SL Davide D'Amico, ZeClinics show more Company Description/Mission Statement ZePharma is the drug discovery branch of ZeClinics. ZePharma and the older ZeClinics Contract Research Organization branch are focused on the use of zebrafish for drug discovery and development. ZePharma has significantly shortened the time took to discover new therapeutic molecules, by utilizing ZeCardio, a zebrafish-based innovative high-throughput screening platform, developed by ZeClinics under the most prestigious grant program from the European Commission, SME Instrument Phase 2. The company is currently developing those molecules in CRISPR-edited pre-clinical models for unmet cardiovascular needs. Implying zebrafish in early R&D steps, allows ZePharma to screen thousands of other molecules in a short space of time and gain in depth understanding of how each molecular structure will target disease. With such business model ZePharma will be continuously fed with new molecular entities to move on drug development and final out-licensing to big pharmaceutical corporations. Time Wednesday, Oct 17 10:45AM - 11:00AM Location Olympic Speakers Davide D'Amico ZeClinics
11:00am Alkahest, Inc. Michael Byrnes, Alkahest, Inc. show more Company Description/Mission Statement Alkahest’s mission is to enrich the health and vitality of humankind through the discovery and development of innovative medicines for the treatment of age-related diseases. Time Wednesday, Oct 17 11:00AM - 11:15AM Location Elizabethan C Speakers Michael Byrnes Alkahest, Inc. Antidote Therapeutics, Inc. Matthew Kalnik, Antidote Therapeutics, Inc. show more Company Description/Mission Statement We are a science-driven biopharmaceutical company developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Our initial development strategy of treating existing disease to improve medical outcomes – rather than preventing future smoking-related illnesses that may occur decades later – is significantly different from how other drugs that target nicotine’s actions have been developed as aids to smoking cessation. The first indications for Antidote’s anti-nicotine drugs are the treatment of orphan vascular diseases in smokers. Unlike FDA-approved smoking cessation drugs, our candidates do not contain nicotine or interact with nicotine-receptors, our anti-nicotine therapeutics are designed to trap or eliminate nicotine in the blood, having the dual benefit of neutralizing nicotine’s direct, harmful effects on organs throughout the body and preventing nicotine from reaching the brain, thereby reducing the addictiveness of nicotine from tobacco products Time Wednesday, Oct 17 11:00AM - 11:15AM Location Olympic Speakers Matthew Kalnik Antidote Therapeutics, Inc. Dr. Reddy's Laboratories Wenn Sun, Dr. Reddy's Laboratories show more Company Description/Mission Statement Dr. Reddy’s Laboratories is an integrated pharmaceutical company, headquartered in Hyderabad, India, committed to providing affordable and innovative medicines for healthier lives. Through our three businesses— Pharmaceutical Services and Active Ingredients; Global Generics; and Proprietary Products— Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. Time Wednesday, Oct 17 11:00AM - 11:15AM Location Elizabethan D Speakers Wenn Sun Dr. Reddy's Laboratories Heidelberg Pharma AG Jan Schmidt-Brand, Heidelberg Pharma AG show more Company Description/Mission Statement Heidelberg Pharma is a publicly listed, biopharmaceutical company focused on oncology. It is the first company developing the toxin Amanitin into cancer therapies, using ist proprietary Antibody Targeted Amanitin Conjugates (ATAC) technology. In addition to collaborating with partners, Heidelberg Pharma is increasingly focused on developing its own ATAC candidates. Its lead ATAC product candidate HDP-101, is being developed for the treatment of mulitple myeloma using a BCMA (B-cell maturation antigen) antibody. HDP-101 has demonstrated strong efficacy and good tolerability in several animal models. A Phase I/IIa clinical trial with HDP-101 is planned to start by mid of 2019. Time Wednesday, Oct 17 11:00AM - 11:15AM Location Elizabethan A Speakers Jan Schmidt-Brand Heidelberg Pharma AG Immunic AG Daniel Vitt, Immunic AG show more Company Description/Mission Statement Immunic is a specialist for best-in-class oral therapies for chronic inflammatory and autoimmune diseases. The company has two products in development with IMU-838 currently in phase 2b testing in patients with ulcerative colitis. The second program, IMU-935, is aiming to be tested in a first in man clinical phase 1 trial early next year. This trial will also test IMU-935 in a patient cohort with psoriasis. Within the next 2-3 years, Immunic plans to deliver multiple read-outs of clinical therapeutic efficacy for both products. Time Wednesday, Oct 17 11:00AM - 11:15AM Location Elizabethan B Speakers Daniel Vitt Immunic AG
11:15am Infinity Pharmaceuticals, Inc. Jayne Kauffman, Infinity Pharmaceuticals show more Company Description/Mission Statement We are an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. We are focusing our efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. Time Wednesday, Oct 17 11:15AM - 11:30AM Location Elizabethan C Speakers Jayne Kauffman Infinity Pharmaceuticals Innova Therapeutics Robert Ryan, Innova Therapeutics show more Company Description/Mission Statement Innova Therapeutics is a dedicated biotech developing innovative therapies for people living with rare diseases, for which there are no effective treatments. There are two novel programs, one at the late pre-IND stage for topical and systemic treatment of inflammatory/autoimmune diseases and another completed Phase 2 in two genetic diseases (OPMD and SCA). Innova Therapeutics is comprised of executives who previously founded and developed a topical therapy for Epidermolysis Bullosa for Scioderm. The management team moved the development of a topical therapy from Pre-IND to Phase 3 in less than 2 years, resulting in partnering the company in 2015 as the 4th highest VC-backed exit (spent $22M and total deal structure appr. $957M). Scioderm was the first biotech company to receive Breakthrough therapy designation and listed as one of the most promising Biotechs by Fierce Biotech (Fierce 15). Time Wednesday, Oct 17 11:15AM - 11:30AM Location Olympic Speakers Robert Ryan Innova Therapeutics NeoTX Holdings Ltd. show more Company Description/Mission Statement NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements. Time Wednesday, Oct 17 11:15AM - 11:30AM Location Elizabethan B OncoTAb, Inc. Rahul Puri, OncoTAb, Inc. show more Company Description/Mission Statement OncoTAb’s vision is to develop and commercialize a continuum of products to address unmet needs in breast and pancreatic cancer diagnosis and treatment. The technology platform on which these products are being developed is a patented monoclonal antibody (TAB004) that specifically recognizes the tumor form of MUC1 (tMUC1) on breast cancer cells and does not recognize normal MUC1/breast epithelia. Fully humanized TAB004 (hTAB004) has been used to demonstrate imaging breast and pancreatic cancer in-vivo, with localization of hTAB004 on tumors but not on healthy tissue. The company successfully demonstrated exquisite targeting of triple negative breast cancer (TNBC) xenograft tumors with Actinium-225 labeled hTAB004 under a Phase 1 contract award from the NCI. The treated animals showed 90% regression of tumors and 100% survival. hTAB004 is a strong candidate for ADC's targeting TNBC and pancreatic cancers. OncoTAb is seeking a strategic partnership to develop hTAB004 for therapy. Time Wednesday, Oct 17 11:15AM - 11:30AM Location Elizabethan A Speakers Rahul Puri OncoTAb, Inc. VIVUS, Inc. John Amos, VIVUS, Inc. show more Company Description/Mission Statement VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. Time Wednesday, Oct 17 11:15AM - 11:30AM Location Elizabethan D Speakers John Amos VIVUS, Inc.
11:30am Acquist Therapeutics, Inc. show more Company Description/Mission Statement Relburn/Acquist develops small molecules that deplete uric acid (UA), an established inflammatory mediator in NASH and gout, conditions with high prevalence and grossly unmet need. Our drugs block lipogenesis and NASH progression in models with elevated UA (~40% of patients). In liver cells, we sharply reduce UA, triglycerides, lipogenesis, and inflammation. Our drugs bifunctionally inhibit regulators of both UA production and excretion (xanthine oxidase and URAT1) at potencies that exceed monofunctional drugs (e.g., allopurinol, febuxostat and lesinurad). Our clinical drug prototype (RLBN1001) reduced UA below targets in 100% of patients. Our executives have extensive experience in drug development. Global composition patents are wholly owned. Optimized for 1st-line, once-daily oral dosing, our lead (RLBN1127) is completing animal tox to confirm activity in biomarker-defined populations. We are raising a Series A and are interested in meeting qualified investors and partners. Time Wednesday, Oct 17 11:30AM - 11:45AM Location Elizabethan B ArtGene Therapeutics Scott Maguire show more Company Description/Mission Statement ArtGene Therapeutics is a pre-clinical stage company that is developing non-viral gene therapy targeted against cardiovascular diseases. Our lead drug candidate - ART-101 - is a 2nd generation of Neovasculgen - an approved and used drug in Russia. It has same mechanism of action and active molecule, thus is a de-risked project guaranteed to be safe and effective. Time Wednesday, Oct 17 11:30AM - 11:45AM Location Olympic Speakers Scott Maguire Eli Lilly and Company Matthew Yates, Eli Lilly and Company show more Company Description/Mission Statement About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly. com and http://newsroom.lilly.com/social-channels. Time Wednesday, Oct 17 11:30AM - 11:45AM Location Elizabethan D Speakers Matthew Yates Eli Lilly and Company Nurix, Inc. Arthur Sands, Nurix, Inc. show more Company Description/Mission Statement Nurix discovers and develops small molecule drugs that control the levels of disease-associated proteins to provide new treatments for unmet medical needs. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our initial focus is on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immune-oncology. Time Wednesday, Oct 17 11:30AM - 11:45AM Location Elizabethan A Speakers Arthur Sands Nurix, Inc. Regrow Biosciences Pvt Ltd SATYEN SANGHAVI, REGROW BIOSCIENCES PVT LTD show more Company Description/Mission Statement Regrow Biosciences Pvt Ltd, pioneering Cell Therapy in India, is a leading biotechnology company focused at delivering the most advanced cell therapy treatments. Founded in 2009, having state-of-the-art technology & 25+ Research scientists, has led the development of Cell Therapy based First two Living Drug(s) in orthopedic segment in India and World's First Cell based drug for Urological disorders. The orthopedic cell therapy products are commercialized and marketed in India. With the record of 700+ cases in India and securing the family of patents for all the products, Regrow is now expanding its footprints globally, including USA, Europe and Japan. Vision: Improving human healthcare by innovating and delivering regenerative medicine based healthcare solutions” Mission: To become the world's largest stem cell based tissue and organ development factory. Time Wednesday, Oct 17 11:30AM - 11:45AM Location Elizabethan C Speakers SATYEN SANGHAVI REGROW BIOSCIENCES PVT LTD
12:00pm Fireside Chat-Ed Hurwitz, JD, MBA, Managing Director, MPM Capital Ed Hurwitz, JD, MBA, MPM Capital; Susanne Mulligan , BMO show more Session Description Ed Hurwitz is an accomplished biotech executive and investor. Prior to joining MPM, he was founder and Managing Director of Precision BioVentures where he focused on founding and seeding start-up biotechnology companies, including Viewpoint Therapeutics. Prior to that, he was a Director at Alta Partners where he led 12 successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics and Taligen Therapeutics (acquired by Alexion). Over the course of his career, he has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotech research analyst for both Robertson Stephens & Company and Smith Barney Shearson. Prior to that he practiced law at Cooley Godward LLP. Ed earned his J.D. and M.B.A. degrees from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, and his B.A. in Molecular Biology from Cornell University. Moderator: Susanne Mulligan, Managing Director, BMO Capital Markets Time Wednesday, Oct 17 12:00PM - 1:25PM Questions

Submit panelist questions here.

Speakers Ed Hurwitz, JD, MBA MPM Capital Susanne Mulligan BMO
2:00pm Berlin Cures Holding AG Johannes Mueller, Berlin Cures show more Company Description/Mission Statement Berlin Cures is rapidly emerging as the only company with an effective and practical treatment for removing autoantibodies that cause disease in about 80 percent of heart failure patients with DCM. As we have completed a Phase 1b study and prepare to launch a Phase 2 study in 2018 on a DNA aptamer-based compound known as BC 007, we have already demonstrated that our approach has unique benefits for heart failure treatment. Our technology platform is also the foundation for developing drugs that hold promise for treating other diseases associated with autoantibodies, such as pulmonary hypertension, glaucoma, and preeclampsia. Time Wednesday, Oct 17 2:00PM - 2:15PM Location Olympic Speakers Johannes Mueller Berlin Cures Cytosen Therapeutics Trent Carrier, CytoSen show more Company Description/Mission Statement CytoSen Therapeutics is a private biopharmaceutical company bringing innovation to NK cell therapy by generating large numbers of highly-active natural killer cells with its particle-based “expansion and activation” process. Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer. Unlike many cellular immune products being investigated today, CytoSen’s unique, patented methods produce scalable cellular immunotherapeutics that have the potential to treat a myriad of cancer types through both personalized and universal donor sources. Our NK Cell Expansion and Activation Technology is the future in NK cell therapies, unparalleled among commercial solutions for generating large doses of primary NK cells with the highest anti-tumor activity. Time Wednesday, Oct 17 2:00PM - 2:15PM Location Elizabethan B Speakers Trent Carrier CytoSen Merck & Co., Inc. Alex Szidon, Merck show more Company Description/Mission Statement A Legacy of Innovation Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From Merck’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. Partnering With Merck In 2017, over 60% of our human health sales were attributable to alliance partnerships and patents. With more than 100 significant business development transactions since 2016, our team has experience working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at merck.com/licensing. Time Wednesday, Oct 17 2:00PM - 2:15PM Location Elizabethan D Speakers Alex Szidon Merck Reaching Chinese Investors: Considerations for an IPO in Hong Kong Joshua Berlin; Keting Chu, Lyfe Capital; Jie D’Elia, Bristol-Myers Squibb; Alexis Ji, Illumina Ventures; Michael Keyoung, C-Bridge Capital show more Time Wednesday, Oct 17 2:00PM - 2:55PM Questions

Submit panelist questions here.

Speakers Joshua Berlin Keting Chu Lyfe Capital Jie D’Elia Bristol-Myers Squibb Alexis Ji Illumina Ventures Michael Keyoung C-Bridge Capital
ViaCyte, Inc. Paul Laikind, ViaCyte, Inc. show more Company Description/Mission Statement ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two product candidates in clinical-stage development: PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for high-risk type 1 diabetes patients. The PEC-Encap™ product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin. Time Wednesday, Oct 17 2:00PM - 2:15PM Location Elizabethan C Speakers Paul Laikind ViaCyte, Inc.
2:15pm American Gene Technologies Jeff Galvin, American Gene Technologies show more Company Description/Mission Statement AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: immune-oncology, infectious disease, and monogenic disorders. AGT expects to take its patented lead candidate for an HIV Cure into the clinic in 2019, and has a novel immuno-oncology(I/O) approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel I/O approach have already been granted, and AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine. AGT has developed a (patent-pending) modified gene that is able to express therapeutic levels of phenylalanine hydroxylase (PAH) which it is deploying, for development of a cure for Phenylketonuria (PKU). AGT expects to begin clinical activities for PKU in 2019, and liver cancer (AGT’s first I/O therapy) in 2020. Time Wednesday, Oct 17 2:15PM - 2:30PM Location Elizabethan D Speakers Jeff Galvin American Gene Technologies Aro Biotherapeutics show more Company Description/Mission Statement Aro Biotherapeutics is focused on developing breakthrough medicines from protein design to patients. Our proprietary Centyrin technology platform is based on protein engineering which creates simple, small, stable, selective, and soluble proteins that can be customized as bi, tri, or multispecific targeting agents. Centyrins can deliver a variety of payloads, including chemotoxins, nucleic acids for gene-modification or, peptides, and other "undruggable drugs". Time Wednesday, Oct 17 2:15PM - 2:30PM Location Elizabethan A DotBio Pte. Ltd. Ignacio Asial, DotBio Pte. Ltd. show more Company Description/Mission Statement DotBio is an early-stage Biopharma company specialized in next-generation antibody therapies, with a particular focus in immuno-oncology. DotBio has a proprietary humanized, stable Domain Therapeutic Antibody (“DotBody”) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and CAR-T therapies. We currently possess proprietary state-of-the-art DotBody and Fab phage display libraries, as well as numerous pre-clinical assets in the immuno-oncology field. Time Wednesday, Oct 17 2:15PM - 2:30PM Location Elizabethan B Speakers Ignacio Asial DotBio Pte. Ltd. Embera NeuroTherapeutics, Inc. Bob Linke, Embera NeuroTherapeutics, Inc. show more Company Description/Mission Statement Embera is a clinical stage pharma company focused on smoking cessation, cocaine use disorder (CUD) and other significant stress mediated diseases. Embera is developing a novel, patented drug combination (EMB-001) targeting the stress response system and specific brain functions that drive craving and relapse related to these addictions. A pilot clinical study in cocaine-dependent human subjects has been completed, showing the potential for EMB-001 to be effective in this disorder. Embera’s lead development programs are CUD and smoking cessation. Embera also completed an animal study in nicotine addiction in which EMB-001 was shown to be significantly more effective than Chantix®, Pfizer’s $998M smoking cessation product. Embera has completed its Phase 1 clinical program and is advancing CUD and smoking cessation products into Phase 2 clinical development. The EMB-001 CUD Phase 2 development program is supported by an $11.1M NIH grant. Time Wednesday, Oct 17 2:15PM - 2:30PM Location Elizabethan C Speakers Bob Linke Embera NeuroTherapeutics, Inc. RECARDIO Inc. show more Company Description/Mission Statement RECARDIO is a Phase 2 life science company developing the therapeutic platform for drug based regenerative therapies for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. Time Wednesday, Oct 17 2:15PM - 2:30PM Location Olympic
2:30pm Arpeggio Biosciences, Inc. Daniel Weaver, Arpeggio Biosciences, Inc. show more Company Description/Mission Statement Arpeggio Biosciences delivers novel insights about a compound’s biological mechanism of action and discovers new therapeutically relevant targets. Our technology combines state-of-the-art nascent transcript sequencing with proprietary algorithms to identify the drivers of biological responses to drug treatment and other environmental perturbations. We identify changes in gene expression (mRNA), enhancer activity (eRNA), and transcription factor activity minutes after treatment. No other technology can track these rapid changes and explore longer term impacts of a drug or other biological response. These results provide our collaborators with valuable insight into drug development that can reduce costs and rapidly lead to higher quality drugs candidates. Also, we are building a complete gene network map that correlates disease state, drug sensitivity, and transcription factor activity. We will use these data to identify novel therapeutic targets and molecular diagnostic marke Time Wednesday, Oct 17 2:30PM - 2:45PM Location Elizabethan A Speakers Daniel Weaver Arpeggio Biosciences, Inc. Axsome Therapeutics, Inc. Herriot Tabuteau, Axsome Therapeutics, Inc. show more Company Description/Mission Statement Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications. Time Wednesday, Oct 17 2:30PM - 2:45PM Location Elizabethan C Speakers Herriot Tabuteau Axsome Therapeutics, Inc. EnduRx Pharmaceuticals Inc. show more Company Description/Mission Statement EnduRx is advancing a novel, nanoparticle-based, actively-targeting drug delivery system Our focus is hard-to-treat solid tumors. Target of the prototype drug is a ubiquitous protein that is surface-expressed ini nutritionally-deprived tumor tissue, and the prototype molecule transports a cytotoxic payload into and throughout the tumor microenvironment in a matter of minutes, developing therapeutically-effective concentrations. Toxicity during delivery is low as the prodrug is not activated until it is bound to the target cell-surface protein. A $1.75MM grant yielded promising data in mouse models of triple-negative breast cancer and glioblastoma. Our novel MOA, orthogonal to other oncology drugs, offers oncologists a new tool with which to address resistance and escape. We expect the delivery system to present multiple opportunities to transport approved and developmental drugs into tumor microenvironments, presenting a spectrum of opportunities for partnerships. Time Wednesday, Oct 17 2:30PM - 2:45PM Location Elizabethan B Info Session One-on-One Partnering at JPM Willie Reaves, Biotechnology Innovation Organization (BIO) show more Time Wednesday, Oct 17 2:30PM - 2:45PM Location Olympic Speakers Willie Reaves Biotechnology Innovation Organization (BIO) RubrYc Therapeutics, Inc. Isaac Bright, RubrYc Therapeutics, Inc. show more Company Description/Mission Statement Though early discovery R&D activities produce millions of potential drug candidates, gold-standard analytical methods and tools can not keep pace. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path to information-driven discovery of therapeutic antibodies, and related therapies. Using the RubrYc Discovery Engine, the Company can decode protein interactions through the integration of predictive analytics and biological measurements. This interface-targeted approach allows RubrYc to accelerate pre-clinical therapeutic antibody discovery, while minimizing many of the risks of industry-standard early-stage R&D. Founded in 2017, RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In April, 2018, RubrYc Therapeutics spun out of HealthTell to define its trailblazing role mining protein:protein interfaces to build better therapies. Time Wednesday, Oct 17 2:30PM - 2:45PM Location Elizabethan D Speakers Isaac Bright RubrYc Therapeutics, Inc.
2:45pm BlackThorn Therapeutics Greg Vontz, BlackThorn Therapeutics show more Company Description/Mission Statement BlackThorn Therapeutics is a clinical-stage biopharmaceutical company that uses a novel and robust approach to link behavioral deficits with brain physiology to discover and develop targeted treatments for neurobehavioral disorders. We envision a future where patients with neurobehavioral disorders are quickly recognized, accurately diagnosed and effectively treated. Time Wednesday, Oct 17 2:45PM - 3:00PM Location Elizabethan C Speakers Greg Vontz BlackThorn Therapeutics FenoLogica Biosciences, Inc. Sean MacLeod, FenoLogica Biosciences show more Company Description/Mission Statement Unlocking Opportunities in the New Frontier of Synthetic Biology - FenoLogica enables microbial researchers and bioengineers to do what they haven't been able to before. Our powerful instrumentation and cloud-based software tools are specifically designed to unlock the vital link between genomics and the understanding of biologic traits and behaviors (phenotypes) in cell biology. Functional data from large, synthetically derived, gene-variant cell libraries – using dynamic multiplexed assays – lead to broader experimental inquiry, quicker discoveries, and more precise biologic signatures. This data is critical to advancing everything from genetic related diagnostics and pharmaceutical discovery, to the development of novel biofuels, agriculture, food science and biomaterials. These techniques have promise in solving the cause and cure of disease, helping our planet’s sustainability, and advancing humankind. Time Wednesday, Oct 17 2:45PM - 3:00PM Location Elizabethan D Speakers Sean MacLeod FenoLogica Biosciences Genisphere LLC Tom Bliss, Genisphere show more Company Description/Mission Statement Genisphere provides an innovative DNA-based targeted drug delivery platform called 3DNA®. Genisphere seeks additional partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology, which is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids in a highly targeted manner. Time Wednesday, Oct 17 2:45PM - 3:00PM Location Elizabethan B Speakers Tom Bliss Genisphere Immix Biopharma, Inc Ryan Witt, Immix Biopharma, Inc show more Company Description/Mission Statement Develop transformative therapies for patients Time Wednesday, Oct 17 2:45PM - 3:00PM Location Olympic Speakers Ryan Witt Immix Biopharma, Inc Second Genome, Inc. Karim Dabbagh, Second Genome, Inc. show more Company Description/Mission Statement Second Genome is a clinical stage company focused on discovering and developing therapeutics derived from the microbiome. This is done by utilizing our robust drug discovery platform, which elucidates and interrogates important microbial products that strongly influence human health and disease. These products are empirically tested through standard drug discovery processes, such as cell-based assays and in vivo models, to identify those that positively or negatively influence a particular disease. Second Genome's pipeline includes a P2X7 modulator entering Phase 2 for NASH in 2018, and a preclinical asset entering Phase 1 for mucosal healing in 2019. The company also has exciting, novel data in our immuno-oncology program, further validating the microbiome impact on response to immunotherapy. Our strategy is to move quickly into the clinic using our proprietary platform, partner certain internal assets and offer broad use of our platform for partner's areas of interest. Time Wednesday, Oct 17 2:45PM - 3:00PM Location Elizabethan A Speakers Karim Dabbagh Second Genome, Inc.
3:00pm Daré Bioscience, Inc. show more Company Description/Mission Statement Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. We are initially focused on the areas of contraception, vaginal health and fertility. Our first product candidate, Ovaprene™, is a monthly non-hormonal contraceptive ring that is currently in clinical studies. We founded Daré because we felt product development in women’s reproductive health is fragmented – the two ends of the development spectrum are being adequately addressed but the stages of clinical development between innovation / early clinical development and late stage development / commercialization are underserved, creating a potential opportunity for Daré to fill the gap by taking products from innovation through development. Time Wednesday, Oct 17 3:00PM - 3:15PM Location Elizabethan D Hillstream BioPharma Inc. Randy Milby, Hillstream BioPharma Inc. show more Company Description/Mission Statement Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer. Our competitive advantage is to enhance the safety and efficacy of FDA-approved oncology therapies by encapsulating them in proprietary polymeric nanoparticles comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows us to build a strong patent estate and seek FDA Orphan Drug Designation in specific indications. Our proprietary formulations of bortezomib and oxaliplatin are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA’s 505(b)(2) regulatory pathway, we could expedite the development process and bring these novel formulations to market to offer patients hope. Time Wednesday, Oct 17 3:00PM - 3:15PM Location Elizabethan B Speakers Randy Milby Hillstream BioPharma Inc. Resverlogix Corp. Kenneth Lebioda, Resverlogix Corp. show more Company Description/Mission Statement Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low levels of high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have CKD. Time Wednesday, Oct 17 3:00PM - 3:15PM Location Olympic Speakers Kenneth Lebioda Resverlogix Corp. Satsuma Pharmaceuticals, Inc. John Kollins, Satsuma Pharmaceuticals, Inc. show more Company Description/Mission Statement Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing STS101, a potential best-in-class therapy for acute migraine. STS101 combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and drug delivery device technologies that enable rapid absorption with high bioavailability of drugs delivered via the nose. DHE has multiple therapeutic advantages over other migraine therapies but is not currently available in a fast-acting, patient-friendly, non-injectable preparation. STS101 has undergone extensive preclinical optimization and evaluation. Based on pharmacokinetic data generated to date, Satsuma anticipates STS101 will be highly effective and well-tolerated in a large number of migraine sufferers whose needs are not well served with current therapies, including those with difficult-to-treat migraine types. Time Wednesday, Oct 17 3:00PM - 3:15PM Location Elizabethan A Speakers John Kollins Satsuma Pharmaceuticals, Inc. Zynerba Pharmaceuticals Armando Anido, Zynerba Pharmaceuticals show more Company Description/Mission Statement Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Cannabinoids appear to modulate a number of systems, channels and receptors; as such, they may have the potential to be developed in a number of additional important indications, including anxiety, autism spectrum disorder, neuroprotection, cognitive disorders, sleep disturbance, and treatment for certain neuralgias. The Company's lead product candidate, ZYN002, is currently being developed in Fragile X syndrome (pivotal study) and refractory epilepsies (Phase 2), including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances. Time Wednesday, Oct 17 3:00PM - 3:15PM Location Elizabethan C Speakers Armando Anido Zynerba Pharmaceuticals
3:15pm CFIUS and You: Understanding the Newly Expanded Regulatory Reviews of Cross-Border Investments Lisa Schaefer, BIO; Thilo Hanemann , Rhodium Group; Louis Lehot, DLA Piper; Mark E. Plotkin, Covington & Burling LLP show more Time Wednesday, Oct 17 3:15PM - 4:10PM Questions

Submit panelist questions here.

Speakers Lisa Schaefer BIO Thilo Hanemann Rhodium Group Louis Lehot DLA Piper Mark E. Plotkin Covington & Burling LLP
DelNova, Inc. Mary Gardner, DelNova, Inc. show more Company Description/Mission Statement To develop Innovative Therapies that resolve patient unmet needs using novel drug delivery strategies. Time Wednesday, Oct 17 3:15PM - 3:30PM Location Elizabethan D Speakers Mary Gardner DelNova, Inc. Flaskworks LLC Jennifer Rossi, Flaskworks show more Company Description/Mission Statement Flaskworks aims to transform the manufacture of dendritic cells for the rapidly growing immuno-oncology and dendritic-cell based vaccine markets. These promising therapies utilize cells which are currently developed using costly, error-prone and time-consuming manual techniques. Flaskworks is developing modular, closed and disposable systems able to address the bottlenecks in the manufacture of these promising therapies. Our pipeline of instrumentation and associated consumables for both the manufacture of dendritic cells and the stimulation and expansion of T cells have been developed in a laboratory at Northeastern University and exclusively licensed to Flaskworks. The team has considerable experience developing and commercializing instrumentation for life science and pharma. Significant grant funding and testing at academic medical centers, biotechs and pharma companies has enabled a market ready product to date. Time Wednesday, Oct 17 3:15PM - 3:30PM Location Elizabethan A Speakers Jennifer Rossi Flaskworks IngenoVax LLC Tim Erickson, IngenoVax show more Company Description/Mission Statement IngenoVax has developed and patented Microbial Mimetics (MM), a novel, bio-inspired vaccine platform composed of “fully-synthetic viruses.” MM uniquely addresses the major mechanistic flaws of previously trialed therapeutic cancer vaccines, and of those currently in trials, by supplying the diverse array of immunological signals required to elicit a robust cellular immune response. Founded upon MM, IngenoVax’s mission is to trial and commercialize best-in-class vaccines for solid tumor cancers and infectious diseases. The company’s lead candidate (MM-001) is an off-the-shelf precision immunotherapy targeting a currently undruggable target in a well-defined patient population comprised of pancreatic and colorectal cancers on a tumor-mutation/HLA basis. The MM platform is also readily-loadable with other common- or patient-specific-antigens to treat an even broader range of solid tumor cancers, including melanoma, lung, medullary thyroid, prostate, and breast, among others. Time Wednesday, Oct 17 3:15PM - 3:30PM Location Elizabethan B Speakers Tim Erickson IngenoVax QT Medical Ruey-Kang Chang, QT Medical show more Company Description/Mission Statement QT Medical is a medtech startup focusing on electrocardiogram (ECG). We make the first and only hospital-quality 12-lead ECG for patients to use at home. The first product QT ECG received FDA clearance in May 2018. Our mission is to bring the most useful cardiac test-- 12-lead ECG, to the homes of millions of patients with heart disease. We will focus initially on CRO/clinical trial market and telemedcine, then move on to post-op and home cardiac care later. Time Wednesday, Oct 17 3:15PM - 3:30PM Location Olympic Speakers Ruey-Kang Chang QT Medical Zosano Pharma Corporation John Walker, Zosano Pharma Corporation show more Company Description/Mission Statement Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”) with the potential to transform patient lives and advance patient care. M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology. Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. The drug-coated microneedles physically break through the stratum corneum and penetrate into the epidermis and dermis, where the dry drug coating is dissolved by the surrounding skin interstitial fluid. In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints. Time Wednesday, Oct 17 3:15PM - 3:30PM Location Elizabethan C Speakers John Walker Zosano Pharma Corporation
3:30pm Aural Analytics, Inc. Daniel Jones, Aural Analytics, Inc. show more Company Description/Mission Statement Bringing together decades of research on neurological diseases, artificial intelligence (AI), neuroscience, speech analytics, speech pathology, and mobile software platforms for health monitoring, Aural Analytics has built proprietary metrics that use speech to capture changes in neurological health. Aural Analytics builds custom applications focused on early detection, longitudinal tracking, patient stratification, precise/objective measures, and eventually diagnosis of neurological disease. This technology has been deployed on 4 continents, 6 languages, is device, location, language, disease agnostic and was the recipient of the 2017 Global SCRIP Award for Best Technology Development. The company has been funded by NSF, NIH and has several customers using the technology in market today. Time Wednesday, Oct 17 3:30PM - 3:45PM Location Elizabethan C Speakers Daniel Jones Aural Analytics, Inc. Azitra, Inc. show more Company Description/Mission Statement Azitra Inc. (Azitra) was established in 2014 to leverage the promise of the microbiome to address both skin disease (e.g. eczema, netherton’s, etc.) and adverse skin conditions (e.g. flaky, dry, rough skin). Skin disease and skin problems afflict millions of individuals worldwide. The Company believes that the microbiome holds the key to addressing these challenges and has assembled an experienced team of drug development specialists, microbiologists, biochemists, dermatologists and experts in industrial microbiology to meet its goals. Azitra has robust technical platform and 3 products entering clinical development in 2019. Time Wednesday, Oct 17 3:30PM - 3:45PM Location Elizabethan D Lauren Sciences LLC Susan Rosenbaum, Lauren Sciences LLC show more Company Description/Mission Statement Lauren Sciences LLC leads in Neuroscience as New York biotech committed to development of its novel V-Smart® platform to create robust pipeline of transformative V-Smart® Nanomedicines, consisting of CNS-active drugs that normally do not cross BBB, for Parkinson's, ALS, GBM, Alzheimer's, etc. V-Smart® Nanomedicines encapsulate non-brain penetrant therapeutic agents, “macro” target brain and cross BBB, “micro” target and deliver to specific brain sites, selectively release at target sites, are administered non-invasively. V-Smart® Nanomedicines are revolutionary, game changers, disease-modifying drugs. V-Smart® breakthrough innovation is the global solution for CNS. Lauren Sciences has: 11 foundation grant awards; 6 pre-clinical pipeline products; 18 peer-reviewed journal publications; 30 research presentations; 7 scientific meeting posters; 10 patent family portfolio estate; laboratories/research team in Israel, where V-Smart® technology was invented. Time Wednesday, Oct 17 3:30PM - 3:45PM Location Elizabethan A Speakers Susan Rosenbaum Lauren Sciences LLC Medicure Inc. show more Company Description/Mission Statement Medicure’s vision is to become a leading cardiovascular pharmaceutical company within the U.S, offering a growing product portfolio of cardiovascular products that improve patients’ lives. Time Wednesday, Oct 17 3:30PM - 3:45PM Location Olympic Natsar Pharmaceuticals Venu Raman, Natsar Pharmaceuticals show more Company Description/Mission Statement Natsar Pharmaceuticals, Inc. is an applied research and drug development company developing oncology drugs based upon RNA helicases, ubiquitous enzymes involved in all aspects of RNA metabolism. Based upon a novel target, DDX3, Natsar has developed a first-in-class small molecule, RK-33, that represents a completely new method to treat cancer, targeting DNA repair and cellular bioenergetics. Mission Statement Research and Development that creates hope. Natsar is developing innovative therapies that could deliver profound impact in fighting lung, brain & breast cancer, sarcoma, and many other diseases. Time Wednesday, Oct 17 3:30PM - 3:45PM Location Elizabethan B Speakers Venu Raman Natsar Pharmaceuticals
3:45pm Cytox Ltd Richard Pither, Cytox show more Company Description/Mission Statement Cytox is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Together with leading academic and industrial partners, we are developing a simple and accurate genetic test to predict future risk of cognitive decline and Alzheimer’s Disease (AD). Our polygenic risk score (PRS) tests are being offered via third party genotyping laboratories and are available on a world-wide basis. The Cytox test is being offered in partnership with Thermo Fisher Scientific (Affymetrix) and comprises our proprietary variaTECT microarray, used together with Cytox SNPfitR™ software, supporting analysis with polygenic risk score (PRS) algorithms to identify at-risk individuals. Near-term commercial opportunities to identify subjects for clinical studies (Pharma and Academic consortia) are being developed. Time Wednesday, Oct 17 3:45PM - 4:00PM Location Elizabethan C Speakers Richard Pither Cytox GLAdiator Biosciences, Inc. Terry Hermiston, GLAdiator Biosciences, Inc show more Company Description/Mission Statement GLAdiator Biosciences has developed a proprietary delivery platform for the safer, more selective and effective treatment of cancer. Formed in 2018, the Company’s technology is based on a 2 year collaboration between Bayer HealthCare and Stanford University. The platform exploits a naturally occurring protein domain associated with coagulation factors known as gamma-carboxyglutamic acid (GLA) to selectively target and internalize into cancer through the recognition of the phospholipid phosphatidylserine (PS) that is expressed on the surface of cancer cells. Healthy, normal cells do not expose PS on their cell surface. This targeting selectivity of GLA is supported by pre-clinical in vitro and in vivo studies including biodistribution profiling in healthy animals. The Company is currently screening both traditional (small molecules, biologics) and non-traditional (e.g. nucleotides) therapeutic payloads to identify one or more clinical candidates in the next 18-24 months. Time Wednesday, Oct 17 3:45PM - 4:00PM Location Elizabethan D Speakers Terry Hermiston GLAdiator Biosciences, Inc Heat Biologics show more Company Description/Mission Statement Heat Biologics a biopharmaceutical company that develops immunotherapies to activate a patient’s immune system against cancer through T-cell activation. Time Wednesday, Oct 17 3:45PM - 4:00PM Location Elizabethan A Kedalion Therapeutics, Inc. Peter Noymer, Kedalion Therapeutics, Inc. show more Company Description/Mission Statement Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream(TM) platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with up to an 80% reduction in dose compared to standard eye drops. Efficacy, along with substantially reduced side effects and improved comfort, were all demonstrated in two Phase 1 studies in patients for two different drug classes. Kedalion’s products will leverage the FDA’s 505(b)(2) regulatory pathway to quickly and efficiently bring to market these novel therapies. The company closed a $5 million Series A round in July 2018 to further advance the AcuStream technology and to support additional clinical trials. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com. Time Wednesday, Oct 17 3:45PM - 4:00PM Location Olympic Speakers Peter Noymer Kedalion Therapeutics, Inc. Zenith Epigenetics Ltd. Sanjay Lakhotia, Zenith Epigenetics Ltd. show more Company Description/Mission Statement Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies. Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer. Our strong management team and organization allow us to efficiently and rapidly explore and progress molecules from discovery to clinical development. Our research team, based in Calgary, Alberta, is well-positioned to take advantage of its broad and longstanding experience in epigenetics to become a leader in the discovery of selective BET inhibitors in both oncology and other indications. Time Wednesday, Oct 17 3:45PM - 4:00PM Location Elizabethan B Speakers Sanjay Lakhotia Zenith Epigenetics Ltd.
4:00pm ActoBio Therapeutics Pieter Rottiers, ActoBio Therapeutics show more Company Description/Mission Statement ActoBio Therapeutics, Inc., a subsidiary of Intrexon Corporation (NYSE: XON) and innovative clinical stage biotechnology company, is pioneering a new class of therapeutic agent: ActoBiotics®. They are specifically designed and engineered to yield therapeutic agents for topical delivery, providing potentially disease-modifying treatments for immune-related and other diseases. Since ActoBiotics® are based on the well-characterized food-grade microorganism, Lactococcus lactis, this approach promises safer and more ecacious treatments than injectable agents. A broad portfolio of ActoBiotics® is being developed to treat a number of diseases, focusing primarily on disease areas with high unmet needs in immunotherapy, allergy and tolerance induction, such as Type 1 Diabetes. Time Wednesday, Oct 17 4:00PM - 4:15PM Location Elizabethan A Speakers Pieter Rottiers ActoBio Therapeutics Histogen, Inc. Gail Naughton, Histogen show more Company Description/Mission Statement Histogen is a regenerative medicine company focused on stimulating the body’s stem cells to regenerate tissues and restore youthful function. Its technology is based upon delivering the growth factors and cell-signaling proteins which are naturally secreted by hypoxia-induced multipotent stem cells. The Company’s lead therapeutic product for hair growth has shown success in early clinical trials, addressing a multi-billion dollar market opportunity. Histogen has recently closed a skin care partnership with Allergan for the dermatology market, and is actively seeking a retail skin care partner. Additional applications of Histogen’s technology span multiple therapeutic and aesthetic areas, including wound healing and orthopedics. Time Wednesday, Oct 17 4:00PM - 4:15PM Location Elizabethan B Speakers Gail Naughton Histogen MyopiaCure Suh-Hang (Hank) Juo, MyopiaCure show more Company Description/Mission Statement Myopia (also known as nearsightedness) has become a pandemic eye disease, with an annual global market size of over 67 billion USD. Myopia increases the risk for severe eye complications, and myopia is the leading cause of blindness in Asia. Currently, atropine is the only effective drug to stop myopia progression but atropine has several side effects. There is a high demand for an effective and non-invasive treatment to stop myopia. We have identified a small molecule causing myopia. We have developed a novel patented drug in eyedrop form to cure myopia. The therapeutic effects have been demonstrated in in-house rodent and non-rodent animal studies and confirmed by an independent third party CRO company. Our drug is 3x more effective than atropine, and does not show side effects. The toxicology study also shows no adverse effects. We plan to file IND in 12 months and finish the phase IIa study in 5 years. Our mission is to develop novel and effect eyedrop to stop myopia progression. Time Wednesday, Oct 17 4:00PM - 4:15PM Location Olympic Speakers Suh-Hang (Hank) Juo MyopiaCure Neurotez Inc. show more Company Description/Mission Statement Our mission is to become world leaders in biotechnology, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs that are both safe and efficacious. We are dedicated to excellence, improving lives and serving the public responsibly. Time Wednesday, Oct 17 4:00PM - 4:15PM Location Elizabethan C Sermonix Pharmaceuticals LLC David Portman, Sermonix Pharmaceuticals LLC show more Company Description/Mission Statement Sermonix is a clinical stage biopharma company focused on metastatic breast cancer (mBC) with a mission to solve the problem of acquired endocrine resistance in mBC in the presence of ESR1 mutations. All patients with mBC ultimately progress, and there is a clear lack of efficacious, well-tolerated options after first line failure. Sermonix is developing the extensively studied potent selective estrogen receptor modulator (SERM), lasofoxifene, as a new, targeted endocrine treatment for Estrogen Receptor Positive (ER+) mBC patients with acquired endocrine resistance due to ESR1 mutations. Lasofoxifene is supported by strong in vivo proof of concept in mutation driven resistance, class-leading in vivo activity against visceral metastases, and new late-expiring IP out to 2037. The Sermonix management team has proven success and experience in developing drugs in breast cancer. An IND opens in October 2018, clinical trial results reporting in 2020, and significant value creation in 2-3 yrs Time Wednesday, Oct 17 4:00PM - 4:15PM Location Elizabethan D Speakers David Portman Sermonix Pharmaceuticals LLC
4:15pm View from the Board: Responding to an Acquisition Offer Michael J. O'Donnell, Morrison & Foerster; Corey Goodman, venBio Partners; Linda Grais , Ocera Therapeutics; Nina Kjellson , Canaan Partners; Camille Samuels, Venrock show more Time Wednesday, Oct 17 4:15PM - 5:10PM Questions

Submit panelist questions here.

Speakers Michael J. O'Donnell Morrison & Foerster Corey Goodman venBio Partners Linda Grais Ocera Therapeutics Nina Kjellson Canaan Partners Camille Samuels Venrock
Thursday, October 18
8:30am Expanding the Toolbox of Neurodegeneration Therapies KT Moortgat, AbbVie; Steven Braithwaite , Alkahest ; Carole Ho, Denali Therapeutics; Charles S. Ryan, Neurotrope; Julie Anne Smith, E-Scape Bio Inc. show more Time Thursday, Oct 18 8:30AM - 9:40AM Questions

Submit panelist questions here.

Speakers KT Moortgat AbbVie Steven Braithwaite Alkahest Carole Ho Denali Therapeutics Charles S. Ryan Neurotrope Julie Anne Smith E-Scape Bio Inc.
9:00am IMV Inc. Frederic Ors, IMV Inc. show more Company Description/Mission Statement IMV is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma Time Thursday, Oct 18 9:00AM - 9:15AM Location Elizabethan D Speakers Frederic Ors IMV Inc. Interpace Diagnostics Group, Inc. Jack Stover, Interpace Diagnostics show more Company Description/Mission Statement Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT™, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. Time Thursday, Oct 18 9:00AM - 9:15AM Location Olympic Speakers Jack Stover Interpace Diagnostics SELFA, Inc. Ira Deyhimy, SELFA, Inc. show more Company Description/Mission Statement SELFA is a digital health company intent on bringing laboratory-quality diagnostics for infectious diseases, cardiac, and cancers to the point of care (POC), and ultimately to the home. SELFA’s semiconductor-based biosensor technology is ideally suited to bring about this evolution. SELFA’s technology is broadly applicable and our beachhead application is a rapid diagnostic test for a full panel of respiratory infections (e.g. flu). No available POC products offer rapid and sensitive test for all common respiratory pathogens and accommodate large patient volumes. Time Thursday, Oct 18 9:00AM - 9:15AM Location Elizabethan C Speakers Ira Deyhimy SELFA, Inc. Urigen Pharmaceuticals, Inc. show more Company Description/Mission Statement Urigen Pharmaceuticals specializes in developing innovative products to ameliorate the cause and symptoms associated with urological ailments, specifically Interstitial Cystitis/Bladder Pain Syndrome ("BPS" or "IC/BPS"). Urology represents a specialty pharmaceutical market of approximately 10,000 physicians in the United States. According to the American Urology Association (the "AUA"), urologists treat a variety of ailments of the urinary tract either surgically or medically. These include treating cancer, infections, stone disease, neurogenic bladder, overactive bladder, incontinence, prostate disease and IC/BPS. Many of these indications, we believe, represent significant, underserved therapeutic markets. We currently have one product candidate, URG101, in clinical development, and two other product candidates, URG501 and URG801, in pre-clinical development. Time Thursday, Oct 18 9:00AM - 9:15AM Location Elizabethan B
9:15am Cerebra Health Inc. Dawson Reimer, Cerebra Health Inc. show more Company Description/Mission Statement Cerebra Health is a digital health company focused on improving access to advanced, diagnostic technology for the assessment of sleep and the diagnosis of sleep disorders. Cerebra's commercial strategy centers around a unique, in-home sleep testing service, mySleepStudy.com. This product, previously sold exclusively as a service to Canadian sleep apnea treatment providers, is soon to be relaunched as a direct to consumer product. The Company’s digital service platform provides unmatched capabilities for in-home sleep analysis, with a focus on improved user experience, state-of-the-art diagnosis, and increased operational efficiency enabled by an advanced delivery system. Cerebra's core competency and technological advantage includes world-leading digital sleep biomarkers and analytics - with which the Company is working to revolutionize the understanding of sleep, sleep disorders and their treatment in partnership with leading sleep scientists and researchers. Time Thursday, Oct 18 9:15AM - 9:30AM Location Elizabethan B Speakers Dawson Reimer Cerebra Health Inc. Fusion Genomics Corporation Mohammed Qadir, Fusion Genomics Corporoation show more Company Description/Mission Statement Fusion Genomics is a precision medicine for infectious diseases company. Our mission is to put the power of next-generation sequencing within the reach of physicians enabling precise diagnosis and thus precise prescription. We solve the problem of non-diagnosis of diseases that is highly prevalent in hospital patients eg. around 70% of meningitis/encephalitis patients, 42% of upper respiratory patients, etc. Fusion has developed a platform that enables us to develop easy to use, cost-effective and powerful genomic tests for infectious diseases. Our main product is the ONETest PathoGenome which will diagnose and give clinically relevant genomic information about all known infectious disease in one panel. The platform enables results within 12 hours at 1/10th the cost of comparable whole metagenomic sequencing but with all the information. Time Thursday, Oct 18 9:15AM - 9:30AM Location Elizabethan C Speakers Mohammed Qadir Fusion Genomics Corporoation Invirsa, Inc. Isaiah Shalwitz, Invirsa show more Company Description/Mission Statement Invirsa has discovered the potential of a naturally occurring molecule that is key to the coordinated immune response to infection. Not only does it activate pathways to reduce viral replication, but it also works to reduce excess inflammation, while enhancing the wound healing response. The effects on inflammation and wound healing are very important since the viral injury continues well after the virus is cleared. INV-102's lead indication is viral (adenovirus) conjunctivitis, for which there are no approved therapeutics. However, the greater potential is infectious respiratory disease where we have already demonstrated POC in RSV. There is no other small molecule that reduces both DNA (adenovirus) and RNA (RSV) viral activity, while simultaneously reducing excess inflammation and repairing injury. Invirsa strongly believes that INV-102 is an ideal first line therapeutic for ophthalmic and respiratory disease and recovery. Time Thursday, Oct 18 9:15AM - 9:30AM Location Olympic Speakers Isaiah Shalwitz Invirsa Monarch Biosciences, Inc. Colin Kealey, Monarch Biosciences show more Company Description/Mission Statement MonarchBio is a life sciences company focused on commercializing next generation cell therapy and regenerative medicine products based on its Thin Film Nitinol (TFN) technology platform. MonarchBio's lead product, developed in collaboration with the Fred Hutchinson Cancer Research Center, is a unique platform for local delivery of cell therapies treating solid tumors. The so-called Engineered Lymph Node (ELN) uses a bioactive thin film mesh to deliver cell therapies directly to the site of the tumor. Pre-clinical testing of this approach at Fred Hutch has demonstrated significant efficacy advantages in 5 different animal models of solid tumors. MonarchBio believes that the ELN solves some of the key challenges for cell therapies in solid tumors by delivering ultra-high cell densities directly to the tumor, and then providing a stimulatory micronenvironment to encourage proliferation of the engineered cells and sustained tumor killing. Time Thursday, Oct 18 9:15AM - 9:30AM Location Elizabethan A Speakers Colin Kealey Monarch Biosciences Rain Therapeutics Avanish Vellanki , Rain Therapeutics show more Company Description/Mission Statement Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer. Time Thursday, Oct 18 9:15AM - 9:30AM Location Elizabethan D Speakers Avanish Vellanki Rain Therapeutics
9:30am Chameleon Biosciences Genine Winslow, Chameleon Biosciences (UCSF) show more Company Description/Mission Statement Chameleon Biosciences is a next generation gene therapy company. We are building on current Adeno Associated Virus (AAV) virus technology to make our products invisible to a patient’s immune system and resistant to pre-existing antibodies. Reduced immunogenicity enables repeat dosing which doubles the number of severe Hemophilia patients that we can treat as compared to current technologies, increasing the accessible market by ~9B (US and EU). Chameleon technology changes the current single dose paradigm by using AAV based gene therapies for precise dosing with repeated gene delivery as needed to maintain clinical efficacy in dividing and non-dividing cell types. Chameleon is focusing initially on treating rare orphan diseases beginning with Severe Hemophilia and Niemann Pick Type C. Our platform technology can be applied to all current gene therapy markets, new markets in rare diseases, and non-orphan disease markets. Time Thursday, Oct 18 9:30AM - 9:45AM Location Elizabethan A Speakers Genine Winslow Chameleon Biosciences (UCSF) Click Therapeutics, Inc. David B. Klein, Click Therapeutics, Inc. show more Company Description/Mission Statement Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. Time Thursday, Oct 18 9:30AM - 9:45AM Location Elizabethan B Speakers David B. Klein Click Therapeutics, Inc. Codagenix, Inc. J. Robert Coleman, Codagenix, Inc. show more Company Description/Mission Statement Codagenix, is a clinical stage, venture and public sector funded synthetic biology company utilizing rational viral design to construct designer vaccines as well as potent and targeted oncolytic viruses. To date we have raised $14M and have an established partnership in the agricultural vaccine space. For our vaccines pipeline we recently completed a Phase I/II clinical trial with our Universal Influenza Vaccine demonstrating safety similar to placebo and induction of broad, multi-decade immunity. We also plan to be in the clinic with our RSV vaccine in 2019. For oncolytics we have rationally designed a potent viral immun-oncology therapy with demonstration of preclinical efficacy. We are planning to raise a Series B ($17M) in Q1-19 to support our Universal Flu Phase II, our RSV Phase I, and potential a Phase I with our oncolytic virus. We already have commitments to join the B from Euclidean Capital and a Large Pharma VC; thus, we are seeking additional syndicate members. Time Thursday, Oct 18 9:30AM - 9:45AM Location Olympic Speakers J. Robert Coleman Codagenix, Inc. Diacarta Inc Lydia Meyer-Turkson, DiaCarta Inc show more Company Description/Mission Statement Redefining Precision Molecular Diagnostics DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. Time Thursday, Oct 18 9:30AM - 9:45AM Location Elizabethan C Speakers Lydia Meyer-Turkson DiaCarta Inc Genprex, Inc. Julien Pham, Genprex, Inc. show more Company Description/Mission Statement Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based on our novel proprietary technology platform, including our initial product candidate - Oncoprex™ immunogene therapy - or, Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. We are currently conducting the second phase of a Phase I/II clinical trial Time Thursday, Oct 18 9:30AM - 9:45AM Location Elizabethan D Speakers Julien Pham Genprex, Inc.
9:45am Accelerating Biotech R&D through Cloud Computing Elliot Menschik, Amazon/Amazon Web Services; Matt Brauer, Third Rock Ventures; Karina Chmielewski, Third Rock Ventures; Pablo Gersberg, BlackThorn Therapeutics; David Konerding, insitro ; Craig Muir, Third Rock Ventures; Charles Wolfus, MyoKardia show more Time Thursday, Oct 18 9:45AM - 10:40AM Questions

Submit panelist questions here.

Speakers Elliot Menschik Amazon/Amazon Web Services Matt Brauer Third Rock Ventures Karina Chmielewski Third Rock Ventures Pablo Gersberg BlackThorn Therapeutics David Konerding insitro Craig Muir Third Rock Ventures Charles Wolfus MyoKardia
Caribou Biosciences Timothy Herpin, Caribou Biosciences show more Company Description/Mission Statement Caribou Biosciences is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. We are using a next-generation gene editing technology to develop a pipeline of off-the-shelf CAR-T cell therapies for the treatment of cancer. We are also using gene editing to develop novel microbiome-based therapies. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. The company is located in Berkeley, California. Time Thursday, Oct 18 9:45AM - 10:00AM Location Elizabethan A Speakers Timothy Herpin Caribou Biosciences ImCare Biotech Aaron Lu, ImCare Biotech show more Company Description/Mission Statement ImCare Biotech, LLC is a biotechnology company situated in Doylestown, PA. The company's primary products in development are innovative diagnostic biomarkers as well as developmental drugs for the treatment of liver diseases such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Its leading product, HepatoDetect® is a serum based diagnostic immunoassay that is significantly more sensitive and specific in detecting liver cancer than existing generations of immunoassays and is effective for detecting HCC including in its early stages. Time Thursday, Oct 18 9:45AM - 10:00AM Location Elizabethan C Speakers Aaron Lu ImCare Biotech Immunomic Therapeutics, Inc. Bill Hearl, Immunomic Therapeutics, Inc. show more Company Description/Mission Statement Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the precursor to UNITE, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and UNITE technology, visit www.immunomix.com. Time Thursday, Oct 18 9:45AM - 10:00AM Location Elizabethan D Speakers Bill Hearl Immunomic Therapeutics, Inc. SaNOtize Research and Development Corp Gilly Regev, SaNOtize Research and Development Corp show more Company Description/Mission Statement Nitric Oxide (NO) is an antimicrobial, anti-inflammatory, vasodilator and wound healing promotor. SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution - platform technology, to treat and prevent microbial infections. SaNOtize found the way to deliver nitric oxide, without the gas cylinders, in a way that is safe to the patient but lethal to all microbes, including drug resistant. 

Target indications include treatment for strep throat, onychomycosis, sinusitis, acne and cold and flu prevention. The company has successfully completed a phase I clinical trial for foot fungal infection, with a No Objection Letter from Health Canada, showing safety and efficacy.  The two founders, Dr. Regev and Dr. Miller, have a combine of 40 years of clinical research experience, with over 25 years in nitric oxide field. Both have successfully brought nitric oxide based drugs and devices to clinical development. Time Thursday, Oct 18 9:45AM - 10:00AM Location Olympic Speakers Gilly Regev SaNOtize Research and Development Corp Trimeric Therapeutics, Inc. John Commissiong, Trimeric Therapeutics, Inc. show more Company Description/Mission Statement Our lead drug candidate, MANF, was designed to treat Parkinson’s disease (PD), and later shown to be effective in retinal diseases as well. MANF is a neurotrophic factor (NTF), and an endoplasmic reticulum (ER) stress response (SR) protein, localized in the ER/Golgi complex. It is also secreted. The USPTO and EPO have awarded MANF orphan drug designation (ODD) for retinitis pigmentosa (RP). MANF is effective in animal models of PD, and in rodent models of RP and glaucoma.There are10-M PD patients worldwide, with 1.0-M in the US. Reimbursement will likely average $100,000 initially in the US and Europe. All MANF-related IP will be transferred from Amarantus Bioscience to Trimeric Therapeutics. We are seeking seed capital of $3.0-M to implement specific milestones, with an IND for PD, projected for Q4/2019. Projects: Manufacture of cGMP MANF protein (Catalent); toxicology; PK/PD; Hire CDO and VP Reg Affairs. Sr Man: Saad Naseer, MD, MBA: CEO & CMO: John Commissiong, PhD: Pres & CSO: Time Thursday, Oct 18 9:45AM - 10:00AM Location Elizabethan B Speakers John Commissiong Trimeric Therapeutics, Inc.
10:00am 20/20 GeneSystems, Inc. show more Company Description/Mission Statement 20/20 is now marketing in the U.S. the first multi-cancer screening blood tests powered by machine learning algorithms built from real-world data of tens of thousands of individuals screened for cancer over 15 years. Time Thursday, Oct 18 10:00AM - 10:15AM Location Elizabethan B Fusion Pharmaceuticals Inc. John Valliant, Fusion Pharmaceuticals Inc. show more Company Description/Mission Statement Fusion is a clinical stage company focused on developing novel targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Our first product, FPX-01, combines the precise targeting of a human experienced antibody with Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer cell death. A clinical trial on FPX-01 is planned for early 2018. Time Thursday, Oct 18 10:00AM - 10:15AM Location Elizabethan D Speakers John Valliant Fusion Pharmaceuticals Inc. GenomeMe Lab Inc. Mohammad Tabesh, GenomeMe show more Company Description/Mission Statement GenomeMe is an antibody developer and manufacturer with a focus on Precision Diagnostics. GenomeMe's product lines include IHC grade antibodies used as companion diagnostics to detect, characterize, and inform treatment options for cancer patients. GenomeMe is the only company in the world with complete A-Z expertise in antibody development and commercialization. With over 73 hybridoma clones established and commercialized in the past 12 months for diagnostic applications, GenomeMe is fast becoming an industry leader. Our current portfolio includes important diagnostic markers such p16, PD-L1, Her2, IDH1 R132H, and BRAF V600E as well as immunotherapeutic targets such as PD-1, GITR, RORgT, OX-40, OX-40 Ligand, TIM3, CTLA-4, etc. GenomeMe is currently further characterizing its clones for therapeutic applications. Our initial cell based assays have identified promising candidates for PD-L1 and CTLA-4 based on larger induced cytokine release compared to the FDA approved PD-1 drug. Time Thursday, Oct 18 10:00AM - 10:15AM Location Elizabethan C Speakers Mohammad Tabesh GenomeMe HPBIO Inc. Jiyoung Ahn, HPBIO Inc. show more Company Description/Mission Statement Theragnostics (Drug development) Company using Aptamer Technology. Time Thursday, Oct 18 10:00AM - 10:15AM Location Elizabethan A Speakers Jiyoung Ahn HPBIO Inc. Perthera Inc. Dendy Young, Perthera show more Company Description/Mission Statement Perthera provides a commercialized, proprietary artificial intelligence-based software platform which helps hospitals and oncologists extend cancer patients’ lives. Its proprietary system combines patient medical history, tumor molecular data, and an analysis of relevant medical literature to produce individually ranked, patient-matched therapeutic options. Perthera solves the complicated organizational and financial problems of performing precision medicine in the most effective, efficient, and timely manner. The system is clinically proven to extend progression free survival in pancreatic cancer patients based on a landmark study published in Clinical Cancer Research in June 20181, and has been demonstrated to be “highly cost effective” based on an HEOR analysis completed in Q3 2018. Time Thursday, Oct 18 10:00AM - 10:15AM Location Olympic Speakers Dendy Young Perthera
10:15am Diffusion Pharmaceuticals Inc. David Kalergis, Diffusion Pharmaceuticlas Inc. show more Company Description/Mission Statement Diffusion is a clinical stage biotechnology company. The company is currently enrolling patients in a Phase 3 trial in glioblastoma multiforme (GBM) brain cancer. Diffusion is also set to begin a Phase 2 in-ambulance trial in Stroke in partnership with UCLA. Time Thursday, Oct 18 10:15AM - 10:30AM Location Elizabethan D Speakers David Kalergis Diffusion Pharmaceuticlas Inc. Fry Laboratories, LLC Jeremy Ellis, Fry Laboratories, LLC show more Company Description/Mission Statement Fry Laboratories, LLC is a clinical stage company with a long track record in the development and translation of novel diagnostics technologies into routine clinical use. We are committed to understanding chronic diseases and contributing to their cure through advancements in diagnostics and basic science research. Our signature technology RIDI(TM), Rapid Infectious Disease Identification system, allows for rapid hypothesis free detection of bacteria in clinical samples. We propose to manufacture and distribute kits that will enable clinical labs to perform this advanced diagnostic assay by simplifying the chemistry and bioinformatics hurdles. The kits and systems are sustainable in a clinical laboratory space and are clinically compatible in both reporting and analysis. By democratizing our existing clinical assay we aim to improve patient care globally using the unmatched capability of Next Generation DNA Sequencing. All development at Fry Laboratories, LLC are self funded. Time Thursday, Oct 18 10:15AM - 10:30AM Location Elizabethan C Speakers Jeremy Ellis Fry Laboratories, LLC Incysus Therapeutics, Inc. show more Company Description/Mission Statement Incysus is focused on developing novel off-the-shelf therapies for cancer, with a particular focus on solid tumor cancers. By using modified gamma delta T cells, our technology addresses the challenges that immunotherapies face targeting cold, low-mutation cancers. Its immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since our founding in 2016, we have filed two INDs and initiated several cancer programs that are in early pre-clinical stages. We expect to begin Phase I trials in its two lead programs-the first for patients with leukemia and lymphoma undergoing stem cell transplantation, and the second in patients with newly diagnosed glioblastoma around year-end. Time Thursday, Oct 18 10:15AM - 10:30AM Location Elizabethan A Info Session BIO Business Solutions Kelly Martin, Biotechnology Innovation Organization (BIO) show more Time Thursday, Oct 18 10:15AM - 10:30AM Location Elizabethan B Speakers Kelly Martin Biotechnology Innovation Organization (BIO) Squarex, LLC show more Company Description/Mission Statement We are developing a drug to prevent herpes labialis outbreaks (cold sores) for 6 months with a single topical application. It has proven effective in two separate clinical trials. There are no approved drugs for this indication, and tens of millions of patients. Time Thursday, Oct 18 10:15AM - 10:30AM Location Olympic
10:30am Advancells Vipul Jain, Advancells show more Company Description/Mission Statement Advancells is a research oriented company based in India dedicated to the usage of human stem cells for the treatment of a variety of life threatening and life style diseases. We produce a range of differentiated and un differentiated cell lines derived from various human sources and also produce our patented bio material scaffolds used to seed our cell lines and used in therapeutic purposes. Our cell lines are used by various partner hospitals and doctors around the world for therapeutic purposes and also by research, and academic institutes and pharma companies for research and drug discovery modals. We are moving towards 3D printing of artificial organs which will ultimately use our scaffolds, seeded with our cell lines and hopefully convert to working organ modals that can be used by pharma companies for drug discovery models and ultimately for human transplant. Time Thursday, Oct 18 10:30AM - 10:45AM Location Elizabethan A Speakers Vipul Jain Advancells BendaRx Corp Martin Noel, BendaRx Corp show more Company Description/Mission Statement The company owns the worldwide rights of SKC 1030, a novel chemotherapeutic based on bendamustine, an anticancer agent approved to treat CLL and NHL. SKC1030 is a co-formulation of bendamustine, the active pharmaceutical ingredient (“API”) and a modified cyclodextrin, a non-toxic excipient that together form a molecular complex that is free from the toxic organic solvents which are utilized in the currently marketed formulations of the API, making SKC1030 more stable, safer and clinically more desirable for patients and health providers. SKC1030 has received ODD designation from the FDA. BendaRx intends to file a US 505(b)(2) NDA and monetize the result by selling or out-licensing the drug to a major pharma with global marketing reach. SKC 1030 is patent protected in all major markets until 2031. Time Thursday, Oct 18 10:30AM - 10:45AM Location Elizabethan B Speakers Martin Noel BendaRx Corp Greenwich LifeSciences, Inc. Snehal Patel, Greenwich LifeSciences show more Company Description/Mission Statement GP2 is a breast cancer immunotherapy that in a specific patient population is currently preventing cancer recurrences in the adjuvant setting. GP2 is a 9 amino acid Her2/neu transmembrane peptide delivered intradermally (with GMCSF) for the prevention of breast cancer recurrence following surgery (adjuvant setting) with a phase III clinical trial being planned for delivery of GP2-GMCSF in sequential combination with Herceptin to Her2/neu (3+) over expressor patients. A single blinded phase IIb clinical trial has completed enrollment of 180 patients of which 101 patients are Her2/neu (3+) over expressor patients. Efficacy data at greater than 4 year follow-up shows that there were no recurrences in the 51 Her2/neu (3+) patients treated with GP2-GMCSF-Herceptin, when fully vaccinated with the 6 primary injection series, versus a 12% recurrence rate in the 50 patient placebo arm treated with GMCSF-Herceptin (p < 0.05). Time Thursday, Oct 18 10:30AM - 10:45AM Location Elizabethan D Speakers Snehal Patel Greenwich LifeSciences KIYATEC Matt Gevaert, KIYATEC show more Company Description/Mission Statement Wasted time is the enemy of cancer patients. KIYATEC’s mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible – making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. Time Thursday, Oct 18 10:30AM - 10:45AM Location Elizabethan C Speakers Matt Gevaert KIYATEC Lakewood-Amedex, Inc. show more Company Description/Mission Statement Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU). Time Thursday, Oct 18 10:30AM - 10:45AM Location Olympic
10:45am “Digiceuticals” as a New Class of FDA-Approved Therapeutics: Investment & Partnering Opportunities Ruchita Sinha, Sanofi Ventures; Jeffrey Abraham, Akili Interactive; David Klein , Click Therapeutics, Inc.; Antoun Nabhan , Pear Therapeutics; Lucia Savage, Omada Health show more Time Thursday, Oct 18 10:45AM - 11:40AM Questions

Submit panelist questions here.

Speakers Ruchita Sinha Sanofi Ventures Jeffrey Abraham Akili Interactive David Klein Click Therapeutics, Inc. Antoun Nabhan Pear Therapeutics Lucia Savage Omada Health
Caladrius Biosciences, Inc. show more Company Description/Mission Statement Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2 trial. CLBS14 is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia. Time Thursday, Oct 18 10:45AM - 11:00AM Location Elizabethan A OncoCyte Corporation William Annett, OncoCyte Corporation show more Company Description/Mission Statement OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy and cystoscopic procedures. OncoCyte’s development pipeline is focused on non-invasive confirmatory diagnostic tests for lung, breast, and bladder cancer. OncoCyte’s tests are being developed using proprietary sets of genetic and protein molecular markers that differentially express in specific types of cancer. OncoCyte conducts ongoing research to identify additional molecular markers, acquire or license markers and related technology, and develop tests based on those markers. Time Thursday, Oct 18 10:45AM - 11:00AM Location Elizabethan C Speakers William Annett OncoCyte Corporation Rafael Pharmaceuticals Sanjeev Luther, Rafael Pharmaceuticals show more Company Description/Mission Statement To develop innovative, highly selective, well tolerated and highly effective anti-cancer agents by selectively targeting altered metabolism in cancer cells Immediate Objective: Become a Pancreatic Cancer Company -improve the quality of life of patients with Pancreatic Cancer, which is the deadliest cancer worldwide with very limited treatment options Current Vision: Become a Gastrointestinal Cancer Company - enhancing the lives of patients with Gastrointestinal (GI) Cancers Time Thursday, Oct 18 10:45AM - 11:00AM Location Elizabethan D Speakers Sanjeev Luther Rafael Pharmaceuticals Xyphos Biosciences, Inc. Thorsten Melcher, Xyphos Biosciences, Inc. show more Company Description/Mission Statement Our vision is to provide precision, control, safety and ultimately durable efficacy to CAR-T therapy in cancer. Xyphos is developing treatments for relapsed hematological malignancies and solid tumors using our flexible and controllable CAR-T cell therapy platform called ACCEL™ (Advanced Cellular Control through Engineered Ligands). ACCEL enables precise control of activity and targeting of our universal CAR-T cell, termed convertibleCAR-T™, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells. Building on the success of the pioneer CAR-T therapies, Xyphos is developing best-in-class CAR-T therapy products based on our ACCEL technology which includes our universal convertibleCAR and a family of bispecific, antibody-like adaptor molecules, called MicAbodies™ and MicAdaptors. Time Thursday, Oct 18 10:45AM - 11:00AM Location Elizabethan B Speakers Thorsten Melcher Xyphos Biosciences, Inc.
11:00am Elevian, Inc. Mark Allen, Elevian, Inc. show more Company Description/Mission Statement At Elevian, we develop new medicines to restore regenerative capacity, with the potential to prevent and treat many age-related diseases. Our scientific cofounders, working at Stanford and Harvard, discovered the regenerative effects of young blood. They went on to discover that replenishing a single circulating protein (GDF11) in aged animals to youthful levels can regenerate the heart, brain, muscle and other tissues. We are developing novel therapeutics that modulate GDF11 to treat and prevent age-related diseases including cardiovascular, metabolic, neurodegenerative, and musculoskeletal diseases. We have exclusive worldwide license to the GDF11-related patent portfolio from Harvard and its research partners. Time Thursday, Oct 18 11:00AM - 11:15AM Location Elizabethan A Speakers Mark Allen Elevian, Inc. Genekam Biotechnology AG Sudhir Bhatia, Genekam Biotechnology AG show more Company Description/Mission Statement Genekam is developing most advanced and cost effective solutions for virology (pandemic viruses like influenza, ebola, lassa, SARS as well as mosquito borne pathogens like Zika viruses, West nile virus, Dengue virus, Usutu virus, Yellow fever etc). It focuses on immunology particularly on B-cells to create next generation solutions like human therapeutic antibodies and small molecules. It has developed around 700 different assays for different pathogens. Genekam may be the only company in the world carrying largest collections of assays to detect any influenza virus ranging from H1 to H15 and N1 to N10 circulating around the world. Now it is focusing on development of therapeutic molecules and antibodies to develop the possible treatment for influenza viruses. Its mission is to create a vaccine with zero side effects. Other areas, where Genekam focuses are magnetic beads applications and development of tools to make genetherapy economical and safer. Time Thursday, Oct 18 11:00AM - 11:15AM Location Olympic Speakers Sudhir Bhatia Genekam Biotechnology AG Onconova Therapeutics, Inc. Ramesh Kumar, Onconova Therapeutics, Inc. show more Company Description/Mission Statement Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova is currently enrolling patients in a pivotal Phase 3 trial testing its lead compound, rigosertib, in patients with myelodysplastic syndromes (MDS). Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages. Time Thursday, Oct 18 11:00AM - 11:15AM Location Elizabethan D Speakers Ramesh Kumar Onconova Therapeutics, Inc. Reglagene Holding, Inc. show more Company Description/Mission Statement Reglagene is a platform therapeutics discovery and development company that leverages DNA quadruplexes as master control elements of gene expression. Our focus is oncology as the expression of many intractable oncogene targets is under quadruplex control. Reglagene's lead program is the down-regulation of telomerase reverse transcriptase (hTERT). Reglagene possesses proprietary and drug-like small molecules that block hTERT expression. Restricting hTERT expression accesses non-canonical telomerase biology that results in oxidative DNA damage and cancer cell apoptosis in a matter of days, a therapeutically viable result distinct from classic telomerase enzyme inhibition approaches. In vivo proof of concept has been demonstrated. Reglagene will earn revenue through partnering its assets after achievement of sufficient proof of concept and through research alliances. Reglagene is currently raising a $2M seed round. $1.5M remains unsubscribed. Time Thursday, Oct 18 11:00AM - 11:15AM Location Elizabethan B VERAVAS, Inc. John Forrest, VERAVAS show more Company Description/Mission Statement VERAVAS™ is a diagnostic company with a research facility in Oakdale, MN that will transform the practice of laboratory medicine through novel, breakthrough sample prep technologies. These technologies will address some of the most pressing challenges facing traditional laboratory testing methods while at the same time enhancing the quality of care. Our novel biomarker diagnostic platform VERAPREP™ can quickly commercialize low abundance biomarkers to meet unmet clinical needs, reduce the effects of troublesome sample interferences, and can dramatically reduce the cost of diagnostic testing. Time Thursday, Oct 18 11:00AM - 11:15AM Location Elizabethan C Speakers John Forrest VERAVAS
11:15am Dendreon Pharmaceuticals LLC Jim Caggiano, Dendreon Pharmaceuticals LLC show more Company Description/Mission Statement Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 30,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Time Thursday, Oct 18 11:15AM - 11:30AM Location Elizabethan A Speakers Jim Caggiano Dendreon Pharmaceuticals LLC Navidea Bio Jed Latkin, Navidea BioPharmaceuticals show more Company Description/Mission Statement Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The Company focuses on the development of innovative immunodiagnostic agents and immunotherapeutics that can and will make a difference for individuals, as well as their families, physicians and care givers, touched by devastating conditions like cancer, autoimmune, infectious and inflammatory diseases. For patients and physicians, we aspire to provide innovative immunodiagnostic agents and therapies to improve patient care for serious diseases. Time Thursday, Oct 18 11:15AM - 11:30AM Location Elizabethan C Speakers Jed Latkin Navidea BioPharmaceuticals NOBIO LTD. Yoram Ashery, NOBIO LTD. show more Company Description/Mission Statement Nobio aims to prevent contamination and infection virtually everywhere with a novel, universal antimicrobial technology. Infectious disease account for 15% of global deaths. Treating hospital acquired infections in the US alone costs over $30 billion a year. Nobio’s technology turns commonly used materials into antimicrobial permanently, using proprietary nanoparticles. 22 published studies, including 2 clinical trials, showed strong, long-lasting effect against a broad spectrum of bacteria. First market entry will be in dentistry in 2019, with the first antimicrobial dental restoratives ($1.4B market), for preventing secondary caries, the world’s most common chronic infection. Pipeline includes cements, sealants and implant coatings. Promising animal studies in medical applications (wound-dressing, implants and catheters) as the next application area. In licensing discussions with industry leaders in the above categories, as well as in industrial, infrastructure and consumer products. Time Thursday, Oct 18 11:15AM - 11:30AM Location Olympic Speakers Yoram Ashery NOBIO LTD. STEM to Market Vas Bailey, ARTIS Ventures show more Time Thursday, Oct 18 11:15AM - 11:30AM Location Elizabethan D Speakers Vas Bailey ARTIS Ventures Tradewind BioScience, Inc. show more Company Description/Mission Statement Tradewind is an early stage therapeutics company dedicated to attacking metastatic cancers in new ways. We are currently advancing an antibody therapeutic for ovarian cancer that will treat primary malignancy, existing metastasis and prevent further spread. When highly expressed, our pro-metastatic target predicts for poor patient survival in ovarian and other cancers. Recently, however, it has been confirmed using a genetically engineered mouse model that it is a potent initiating oncogene in the ovary. It has a role in early to late stage ovarian cancer making this an ideal first indication. In vivo, our prototype therapeutic produces a pronounced anticancer effect in several models with no toxicities being noted. Time Thursday, Oct 18 11:15AM - 11:30AM Location Elizabethan B
11:30am Bristol-Myers Squibb Jie D’Elia, Bristol-Myers Squibb show more Company Description/Mission Statement At Bristol-Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Watch to see how Bristol-Myers Squibb delivers on this commitment. Time Thursday, Oct 18 11:30AM - 11:45AM Location Elizabethan D Speakers Jie D’Elia Bristol-Myers Squibb Cyclenium Pharma Helmut Thomas, Cyclenium Pharma show more Company Description/Mission Statement Private company, using proprietary, orally bio-available and brain penetrable, small-molecule macrocycle technology in the discovery of drugs against difficult targets. Advanced lead programs in viral (pan-flavivirus protease inhibitors for the treatment of Dengue, Zika, WNV and JEV infections) and CNS diseases (biased signaling delta-opioid receptor agonists for the treatment of anxiety disorders including PTSD) as well as cystic fibrosis. Cyclenium is seeking A-round financing for the advancement of flavivirus program to IND and clinical Phase 1. Time Thursday, Oct 18 11:30AM - 11:45AM Location Olympic Speakers Helmut Thomas Cyclenium Pharma Digenomix Corporation Larry Xi, Digenomix Corporation show more Company Description/Mission Statement Digenomix is developing an affordable single-cell DNA sequencing methodology, transforming the currently analog form of NGS into a digital form. This digital revolution will allow us to provide a better diagnostic tool and use the tool to guild cancer treatments. We want to change the current cancer treatment model from pharma-centric to patient-centric. Time Thursday, Oct 18 11:30AM - 11:45AM Location Elizabethan B Speakers Larry Xi Digenomix Corporation Xylome Thomas Kelleher, Xylome Corporation show more Company Description/Mission Statement Xylome is a non-conventional yeast biotechnology company that is harnessing the power of genetics to convert low-value by-products from ethanol plants into higher value lipids, chemicals, enzymes and animal feeds. Time Thursday, Oct 18 11:30AM - 11:45AM Location Elizabethan C Speakers Thomas Kelleher Xylome Corporation
12:00pm Fireside Chat—Rowan Chapman, PhD, Head, Johnson & Johnson Innovation, California Rowan Chapman, Johnson & Johnson Innovation, California; Deepa Pakianathan, Delphi Ventures show more Session Description Rowan is the Head of Johnson & Johnson Innovation, California. In this role, Rowan leads the California team to build and manage a portfolio of co-investments spanning all three sectors of Johnson & Johnson. Rowan most recently served as Head of Healthcare Investing, GE Ventures. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. In this role she drove creation of the first three Healthcare “NewCos” incubated and launched from GE. Prior to joining the ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content. Before GE, she spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Her investments ranged from therapeutics to diagnostic to digital. Rowan holds a PhD and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco. Moderator: Deepa Pakianathan, PhD, Managing Partner, Delphi Ventures Time Thursday, Oct 18 12:00PM - 1:25PM Questions

Submit panelist questions here.

Speakers Rowan Chapman Johnson & Johnson Innovation, California Deepa Pakianathan Delphi Ventures
1:45pm How Real-World Evidence Can Improve Clinical Trial Productivity Cartier Esham, Biotechnology Innovation Organization (BIO); Ken Carson, Flatiron Health; Gracie Lieberman , Genentech; Jeremy Rassen, Aetion ; Komathi Stem, monARC Bionetworks show more Time Thursday, Oct 18 1:45PM - 2:40PM Questions

Submit panelist questions here.

Speakers Cartier Esham Biotechnology Innovation Organization (BIO) Ken Carson Flatiron Health Gracie Lieberman Genentech Jeremy Rassen Aetion Komathi Stem monARC Bionetworks
2:00pm BioVaxys LLC show more Company Description/Mission Statement Founded in 2018, BioVaxys LLC is a clinical-stage immuno-oncology company developing a universal vaccine platform for individualized cancer treatment of resectable solid tumors. Based on multihaptenized autologous vaccine technology developed by BioVaxys founder Dr David Berd, BioVaxys will initially be targeting ovarian cancer, melanoma, and other resectable solid tumors. Time Thursday, Oct 18 2:00PM - 2:15PM Location Elizabethan A Cairn Biosciences Mary Ludlam, Cairn Biosciences show more Company Description/Mission Statement Cairn Biosciences is developing next-generation therapeutics that overcome acquired resistance to cancer therapy. Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies. Our approach encompasses cutting-edge advances in microfluidics, synthetic biology-enabled high-throughput screening and induced pluripotent stem cell-based modeling. We industrialize the monitoring of multiple dynamic facets of previously inaccessible biology in live cells, enabling accelerated discovery of a pipeline of drugs for a wide range of indications. Our initial focus is the compelling opportunity to benefit cancer patients by overcoming acquired resistance to PARP inhibitors – a multibillion dollar market. Our vision is a world where killer diseases are relegated to chronic conditions by Cairn’s approach to overcoming disease progression. Time Thursday, Oct 18 2:00PM - 2:15PM Location Elizabethan C Speakers Mary Ludlam Cairn Biosciences Gila Therapeutics, Inc. Thomas Vasicek, Gila Therapeutics, Inc. show more Company Description/Mission Statement Gila is developing breakthrough obesity treatments based on the topical lingual application of natural satiety hormones, which are normally secreted into the bloodstream after we eat to tell us we've had enough. At Gila, we deliver them before you eat so you feel full sooner, eat less & lose weight, with no safety or tolerability issues & no systemic exposure, no absorption into the blood, now demonstrated in mice, rats & dogs at doses up to 10,000x above the therapeutic range. Our patented process exploits the newly described & otherwise unexploited connection between the tongue & the brain, fully activating the satiety response, as strong as a hormone injection or a large meal. We recently completed our phase I clinical trial, fully meeting the safety endpoints while demonstrating a satiety response twice as strong as Saxenda (separate studies, not side-by-side), the leading drug on the market today, an injectable that causes intolerable nausea in 40% of patients. Time Thursday, Oct 18 2:00PM - 2:15PM Location Elizabethan D Speakers Thomas Vasicek Gila Therapeutics, Inc. RHNanopharmacuticals, LLC Izhar Hasan, RHNanopharmacuticals, LLC show more Company Description/Mission Statement RH/Nanopharma is a pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing Osteoarthritis ad Rheumatoid arthritis. We are reintroducing a pre-DESI, proven anti-inflammatory/analgesic agent with a patented, micronized formulation, based on animal data. Salsalate has established equivalent clinical efficacy and enhanced safety profile (cardiac, renal and GI toxicity) compared to traditional NSAIDs. We have completed a Pe IND meeting using 505(b)(2) regulatory pathway for Osteoarthritis. Our plans for IND filing is in progress and we anticipate to submit pharmacokinetic data to FDA in next few months. Time Thursday, Oct 18 2:00PM - 2:15PM Location Olympic Speakers Izhar Hasan RHNanopharmacuticals, LLC X-Therma Inc. Xiaoxi Wei, X-Therma Inc. show more Company Description/Mission Statement X-Therma is developing ground-breaking changes to healthcare by advancing the Regenerative Medicine field’s cold-chain for delivery of fully functional cells, tissues, and whole organs using highly advanced, non-toxic chemistry. Time Thursday, Oct 18 2:00PM - 2:15PM Location Elizabethan B Speakers Xiaoxi Wei X-Therma Inc.
2:15pm Antag Therapeutics ApS show more Company Description/Mission Statement Antag Therapeutics is developing a novel approach to treating dietary-related metabolic diseases, with obesity as our main target indication. The technology originates from the same lab where GLP-1 agonists were discovered, and we have the unique opportunity of validating our novel approach and exploring niche indications by conducting human interventional studies. Time Thursday, Oct 18 2:15PM - 2:30PM Location Elizabethan D FBM Therapeutics Gordon Foulkes, FBM Therapeutics show more Company Description/Mission Statement The company focus is new therapeutics for dermal fibrosis. To date, there are two lead compounds in pre-clinical development. We are seeking $10M to move the first 2 programs through to IND. The first drug candidate, FBM5712, was originally discovered and nominated for clinical development by Pfizer. FBM5712 is a small molecule NCE, and a potent inhibitor of ALK-5, the kinase domain of the TGF-B receptor. The initial clinic indications are keloid scars and scleroderma. There are no approved drugs for either indication. 8kg of API is in-hand, as are candidate clinical formulations. 7 day tox studies have been complete. The second program is an antisense oligo which targets CTGF, a downstream TGF-B pathway. The target indication is hypertrophic scarring, a multibillion market with no approved drugs and where initial clinical proof of efficacy is in-hand. Time Thursday, Oct 18 2:15PM - 2:30PM Location Elizabethan A Speakers Gordon Foulkes FBM Therapeutics Insight RX, Inc. Sirj (Srijib) Goswami, Insight RX, Inc. (UCSF) show more Company Description/Mission Statement InsightRX is a leader in developing and implementing digital therapeutics which augment medicine at the point of care. The core InsightRX precision dosing platform combines patient-specific data with the science of quantitative pharmacology and machine learning to help clinicians individualize dosing at the point of care, augmenting medicine by maximizing efficacy while minimizing toxicity. InsightRX is currently available as a stand-alone or as an EMR integrated product and supports precision dosing for several therapeutic areas including antibiotics, chemotherapeutics and immunosuppressants. Time Thursday, Oct 18 2:15PM - 2:30PM Location Elizabethan B Speakers Sirj (Srijib) Goswami Insight RX, Inc. (UCSF) OrPro Therapeutics Inc. Peter Heifetz, OrPro Therapeutics Inc show more Company Description/Mission Statement OrPro Therapeutics, Inc. is developing a non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus. The company’s core technology based on the human thioredoxin-1 enzyme was licensed exclusively from National Jewish Health, the leading US respiratory hospital, with key patent-protected improvements (the Theradux® platform) developed internally. OrPro’s technology restricts thioredoxin activity to the epithelial surface allowing topical delivery of a target-selective disulfide reductase with extracellular anti-inflammatory and microbial defense-enhancing properties that is capable of normalizing excess viscosity and stiffness of mucus from the lungs of patients with cystic fibrosis (CF). Lead product ORP-100S may both help existing therapies improve pulmonary function and modify disease progression in patients who are not CFTR-modulator candidates. Time Thursday, Oct 18 2:15PM - 2:30PM Location Olympic Speakers Peter Heifetz OrPro Therapeutics Inc RadioMedix Inc Izabela Tworowska, RadioMedix Inc show more Company Description/Mission Statement RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company was founded in 2006 with a primary focus on the commercializing of radiotherapeutics and diagnostics agents for the orphan diseases. RadioMedix has two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical trials and Molecular Imaging Facility for in vitro/in vivo evaluation of agents. Our company has served as a sponsor and collaborator of Phase I/II and Phase III NDA enabling clinical trials. RadioMedix is an US-exclusive distributor of ITG GmbH (Germany) products and Trasis SA (Belgium) automated synthesizers for radiolabeling. RadioMedix serves also as a contract research project organization for partners interested in the development of radiolabeled probes. Time Thursday, Oct 18 2:15PM - 2:30PM Location Elizabethan C Speakers Izabela Tworowska RadioMedix Inc
2:30pm 7 Hills Pharma Upendra Marathi, 7 Hills Pharma show more Company Description/Mission Statement 7 Hills Pharma is an immuno-oncology company developing drugs drug resistant cancers. In spite of the unprecedented cure rates in rare cancers, the promise of immunotherapy and cell therapy is yet to be realized for solid tumors such as lung, colon, and other cancers. 7 Hills is developing cost-effective technologies that modulate the immune system to increase the effectiveness of immune checkpoint blockade, adoptive cell therapy, and cord blood transplant to treat solid tumors and orphan genetic diseases. Time Thursday, Oct 18 2:30PM - 2:45PM Location Elizabethan C Speakers Upendra Marathi 7 Hills Pharma CohBar, Inc. Simon Allen, COHBAR show more Company Description/Mission Statement CohBar is a clinical stage biotechnology company whose mission is to increase healthy lifespan by developing treatments for the underlying metabolic dysfunction driving the diseases of aging including NASH, obesity, cancer, Type 2 diabetes, and cardiovascular and neurodegenerative diseases. Time Thursday, Oct 18 2:30PM - 2:45PM Location Elizabethan D Speakers Simon Allen COHBAR Enlil Therapeutics Alexey Bazarov, Enlil Therapeutics show more Company Description/Mission Statement Enlil Therapeutics was created to develop a first-in class treatment for idiopathic pulmonary fibrosis, an invariably fatal lung disease affecting 100,000 patients in the U.S. alone. In contrast to the two FDA-approved IPF treatments currently available, pirfenidone and nintedanib, our treatment is intended to cure, not merely delay, disease progression. Our initial focus is on a subset of IPF patients with mutations in RNA subunit of telomerase (hTR). The addressable market for this patient population is estimated to be 150-400M a year in the U.S. alone. We will introduce an adeno-associated virus vector expressing a wild-type copy of hTR into lung epithelial cells of IPF patients, restoring normal telomerase activity and reversing the disease progression. Enlil will further develop treatments for IPF caused by other telomere-related genes, as well as for the other telomere-related conditions. Time Thursday, Oct 18 2:30PM - 2:45PM Location Olympic Speakers Alexey Bazarov Enlil Therapeutics New Horizons Pharma Ilana Katsnelson, New Horizons Pharma show more Company Description/Mission Statement New Horizons Pharma is a start-up company specialized on the development of innovative medical treatments for four serious medical conditions related to acute alcohol consumption: alcohol poisoning, alcohol-disulfiram reaction, disulfiram like reaction and Asian flush as well as ischemia-reperfusion injury such as myocardial Infarction. All these life threatening conditions associated with temporary ALDH2 enzyme deficiency and can be treated through IV administration of ALDH2 in an emergency room. This treatment would quickly decrease levels of toxic metabolites in the blood and, thus, prevent severe organ toxicity. Time Thursday, Oct 18 2:30PM - 2:45PM Location Elizabethan A Speakers Ilana Katsnelson New Horizons Pharma Xcell Biosciences Brian Feth, Xcell Biosciences show more Company Description/Mission Statement Xcell Bio is a San Francisco-based company that builds products for immunotherapy development, enabling rapid expansion and phenotypic control of T-Cell, NK cells, and other therapeutic cell types without the need for activating agents, and can selectively enrich for subtypes of interest such as naive and memory cell populations. The company is using this proprietary capability to create a unique, protected position for improving cell therapy efficacy, safety, and persistence. The company is leveraging their platform cell control capability with primary live cell functional readouts and software for multi-parametric analysis enabling predictive and iterative therapy development. Time Thursday, Oct 18 2:30PM - 2:45PM Location Elizabethan B Speakers Brian Feth Xcell Biosciences
2:45pm Applying Artificial Intelligence to Improve Therapy Development Today Gini Deshpande, NuMedii, Inc.; Parvez Ahammad , BlackThorn Therapeutics; Josep Bassaganya-Riera, Landos Biopharma; Jeffrey Brewer, Bigfoot Biomedical; Alex Morgan , Khosla Ventures ; Edward Painter, A2A Pharmaceuticals show more Time Thursday, Oct 18 2:45PM - 3:55PM Questions

Submit panelist questions here.

Speakers Gini Deshpande NuMedii, Inc. Parvez Ahammad BlackThorn Therapeutics Josep Bassaganya-Riera Landos Biopharma Jeffrey Brewer Bigfoot Biomedical Alex Morgan Khosla Ventures Edward Painter A2A Pharmaceuticals
Miromatrix Medical Inc. Jeff Ross, Miromatrix Medical Inc. show more Company Description/Mission Statement Miromatrix is a leading regenerative medicine company bioengineering transplantable organs including livers, kidneys and hearts based on its patented perfusion decellularization and recellularization technology, with collaborators including The Mayo Clinic, Mount Sinai Hospital, and Texas Heart Institute. In addition to whole organ development, Miromatrix has successfully developed, manufactured and commercialized a series of porcine organ-derived biological products. MIROMESH®, is the only liver-derived biologic mesh for soft tissue reinforcement and MIRODERM®, is the only liver-derived wound care product and a recent case-series published in WOUNDS® demonstrated its ability to successfully treat diabetic foot ulcers that had previous failed other advanced biologics. Miromatrix is leveraging these successes with our recellularization technology to fully address the transplantable organ shortage. Time Thursday, Oct 18 2:45PM - 3:00PM Location Olympic Speakers Jeff Ross Miromatrix Medical Inc. Nemus Bioscience, Inc. Brian Murphy, Nemus Bioscience, Inc. show more Company Description/Mission Statement Nemus is a publicly traded (OTCQB:NMUS) biotech company developing derivatives of cannabinoid molecules for the treatment and management of diseases of urgent medical need, especially those involving vision such as glaucoma. The company is developing a prodrug of THC and an analog of CBD. Time Thursday, Oct 18 2:45PM - 3:00PM Location Elizabethan D Speakers Brian Murphy Nemus Bioscience, Inc. Saturn Biosciences show more Company Description/Mission Statement Saturn Biosciences is developing SAT012, a fusion of functional IL12 with a targeting antibody against highly selective tumor antigen ED-B. Interleukin 12 (IL12) is the key anti-tumor cytokine acting by induction of T and NK cells to attack the tumor. IL12 is also the key cytokine to turn "exhausted" CD8+T-cells back on after their exposure to anti-PD1 Abs. "Naked" IL12 has shown good responses as a single agent but with serious side effects. The key advantages of SAT012 over the other developments are its targeted localization of IL12 to tumors to avoid systemic exposure (side-effects) and its much longer half-life than the naked IL12. SAT012 has completed a successful Phase 1 as a monotherapy which established a suitable dose and an efficacy signal that has proven to be superior to other efforts with cytokines. SAT012 is being readied for a Phase 1b/2 in solid tumors in combination with anti-PD1/PDL1 mAbs to increase the hitherto low numbers of responders to anti-PD1/PDL mAbs. Time Thursday, Oct 18 2:45PM - 3:00PM Location Elizabethan C Socium Therapeutics, Inc. Timothy Salmon, Socium Therapeutics, Inc. show more Company Description/Mission Statement Socium Therapeutics is developing an orally administered immunotherapy platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s patented platform – CReST™ (Cross-Presenting Recombinat Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells. Socium is advancing its lead candidate in metastatic castration resistant prostate cancer into a Phase I trial. Time Thursday, Oct 18 2:45PM - 3:00PM Location Elizabethan A Speakers Timothy Salmon Socium Therapeutics, Inc. Universal Sequencing Technology Scott Kozak, Universal Sequencing Technology (UST) show more Company Description/Mission Statement At Universal Sequencing Technology, our solutions will provide technological advancement in the application of DNA sequencing such as genomic and biomedical research, clinical diagnostics of cancer and genetic disease, precision medicine, epidemic prevention, forensic testing, archaeology, and agriculture. Our solutions are easier to use and produce accurate results while providing substantial savings. Tell-Seq enables full-genome sequencing using today's limited sequencing platforms. Our smart barcode technology solves the short sequence reads limitations by enabling 2nd gen sequencers to produce 3rd gen “like” long-read results, which makes the genome assembly easier, more accurate, and further reduces genome sequencing cost by greatly reducing the need for DNA over sampling. A 3rd generation sequencer is our method for nanopore sequencing control. The known technical challenge is control of the movement of DNA through the nanopore. We have solved this issue. Time Thursday, Oct 18 2:45PM - 3:00PM Location Elizabethan B Speakers Scott Kozak Universal Sequencing Technology (UST)
3:00pm Aktivax, Inc Josef Schroeter, Aktivax Inc.; Amir Genosar show more Company Description/Mission Statement Aktivax is a specialty pharmaceutical company developing products utilizing a novel single use auto injector platform called ARAI. We design and develop drug delivery technologies for both defense and consumer emergency treatment applications. Our mission is "Delivering Peace-of-Mind" Time Thursday, Oct 18 3:00PM - 3:15PM Location Elizabethan C Speakers Josef Schroeter Aktivax Inc. Amir Genosar ivWatch, LLC Gary Warren , ivWatch; Scott Hensley, ivWatch, LLC show more Company Description/Mission Statement ivWatch develops and markets biomedical sensor technology products focused on infusion therapy and vascular access. Our market research has found that approximately 46 million IV placements annually are considered “high-risk” due to medication type and patient population, among other factors. Unlike continuous monitors available for heart rate/blood oxygen level, no technology has been available to continuously monitor an IV site and assess if drugs are being delivered to the vein without leakage. ivWatch has received multiple FDA clearances for a device that continuously monitors peripheral IVs for the early detection of infiltration/extravasation events, allowing for earlier intervention. Because of the prevalence of chronic diseases, the IV therapy device and injectable drug delivery markets’ growth projections support our current products and pipeline of new technologies. Regardless of delivery method, ivWatch stands ready to protect patients from harm from drug delivery errors. Time Thursday, Oct 18 3:00PM - 3:15PM Location Elizabethan D Speakers Gary Warren ivWatch Scott Hensley ivWatch, LLC Salarius Pharmaceuticals David Arthur, Salarius Pharmaceuticals show more Company Description/Mission Statement Salarius is leveraging $21M in non-dilutive funds and a management team with over 100 years experience in pharmaceuticals to bring a novel cancer treatment to people who need it the most. Salarius is first targeting a rare pediatric bone cancer so aggressive that patients have less than a 10% chance to survive for five years or more. Next, Salarius is targeting subtypes of breast, ovarian, and prostate cancer representing the #1 causes of cancer-related mortality in men & women. Salarius will be starting Phase 1 trials this month and eyeing a 2020 exit. Time Thursday, Oct 18 3:00PM - 3:15PM Location Elizabethan A Speakers David Arthur Salarius Pharmaceuticals Sernova Corp. Philip Toleikis, Sernova Corp. show more Company Description/Mission Statement Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Time Thursday, Oct 18 3:00PM - 3:15PM Location Olympic Speakers Philip Toleikis Sernova Corp.
3:15pm Abreos Biosciences, Inc. Bradley Messmer, Abreos Biosciences show more Company Description/Mission Statement Precision medicine company developing therapeutics complemented by personalized dosing. Abreos Biosciences is planning to develop a novel therapeutic for treatment of multiple sclerosis, a chronic neurological disease. Our approach will be to study a well characterized biologic in a new indication facilitated by our platform for precision personalized dosing. Time Thursday, Oct 18 3:15PM - 3:30PM Location Elizabethan C Speakers Bradley Messmer Abreos Biosciences Aethlon Medical, Inc. Jim Joyce, Aethlon Medical, Inc. show more Company Description/Mission Statement At Aethlon Medical, we are a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Time Thursday, Oct 18 3:15PM - 3:30PM Location Elizabethan D Speakers Jim Joyce Aethlon Medical, Inc. IGF Oncology, LLC show more Company Description/Mission Statement We are developing targeted cancer drugs with better efficacy and lower side effects than existing cancer drugs. Time Thursday, Oct 18 3:15PM - 3:30PM Location Elizabethan A Orig3n, Inc. Robin Smith, Orig3n, Inc. show more Company Description/Mission Statement Orig3n exists at the intersection of biology and emerging technology, advancing the future of health through regenerative medicine and genetic testing. Orig3n is pursuing allogeneic, iPSC-derived, cell therapy programs in a variety of indications, including osteoarthritis and cardiovascular. We have build the largest cell bank in the world for commercial cell therapy applications, and have identified cell lines from the bank that are matched to the immune profiles of 90% of the US population. Orig3n also offers the largest suite of direct-to-consumer genetic tests, the revenues from which are directed to supporting its cell therapy programs. The founding team are successful serial entrepreneurs with 60+ years of experience in the life sciences. The founders have 3 prior successful exits - the two most recent were VC-backed and both sold to publicly traded companies. The most recent exit provided a 24:1 return and 74% IRR to investors. Time Thursday, Oct 18 3:15PM - 3:30PM Location Olympic Speakers Robin Smith Orig3n, Inc.
4:00pm Market Outlook – IPOs Ascendant and Watching M&A Valuations Rajeev Dadoo, S.R. One Limited; Anna French, Qiming Venture Partners USA; Ken Haas, Abingworth; Matt McAviney, NEA; Jimmy Z. Zhang, LAV (Lilly Asian Ventures) show more Time Thursday, Oct 18 4:00PM - 4:55PM Questions

Submit panelist questions here.

Speakers Rajeev Dadoo S.R. One Limited Anna French Qiming Venture Partners USA Ken Haas Abingworth Matt McAviney NEA Jimmy Z. Zhang LAV (Lilly Asian Ventures)

Please submit panelist questions here

CLOSE
Day

Time























Session Type


Main Therapeutic Focus